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ABSTRACT 
            Currently, acetyl cholinesterase and N-methyl-D-aspartate antagonists are commercially 
available for the treatment of Alzheimer's disease (AD). Approach of using multifunctional 
inhibitors to reduce the side effects of available drugs is the main objective of this work. 
Presently, Histamine-3 (H3) receptor antagonists are used for the treatment of several 
neurodegenerative disorders such as Epilepsy, Alzheimer‘s and Parkinson‘s diseases. Both H3 
and AchE inhibitors cure the symptoms of Alzheimer by enhancing the acetylcholine levels in 
the brain. But the mechanism of action involved in both the cases is different.  Here, we propose 
histamine-3 antagonist with acetyl cholinesterase (AchE) inhibitor activity as a novel class of 
drugs which can be used to treat Alzheimer‘s disease with less adverse peripheral effects caused 
by excessive AchE inhibitor. Our present study can be divided into two parts. In the first part, 
homology modeled structure of H3 active site and available crystal structure of AchE was used to 
collect the information for pharmacophore identification. The important descriptors were 
identified based on comparative 2D-QSAR and 3D-QSAR study of 28 druggable compounds for 
H3 receptor collected from the literature. In the second part, five hybrid molecules were 
generated based on the pharmacophore of H3 receptor and known pharmacophore of AchE 
inhibitors. All five hybrid molecules were screened through ADME/tox filters. The hybrid 
molecule was validated through GOLD docking score in both AchE and H3 receptor. The best 
hybrid compound (hybrid-3) was then evaluated by molecular dynamics (MD) simulation in 
water solvent model using 3D model of human H3 receptor (build based on bovine rhodopsin 
structure). 
 
Keywords: Alzheimer’s disease, Homology model, QSAR, docking, pharmacophore modeling,   
Molecular dynamic study, ADME/tox 
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INTRODUCTION 
Bioinformatics is conceptualizing biology in terms of molecules (in the sense of physical 
chemistry) and applying "informatics techniques" (derived from disciplines such as applied 
math‘s, computer science and statistics) to understand and organize the information associated 
with these molecules, on a large scale. In short, bioinformatics is a management information 
system for molecular biology and has many practical applications. 
 
 
 
Fig 1 Evolution of Bioinformatics 
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Fig.1 represents a paradigm shifts during the past couple of decades have taken much of biology 
away from the laboratory bench and have allowed the integration of other scientific disciplines, 
specifically computing. The result is an expansion of biological research in breadth and depth.  
The vertical axis demonstrates how bioinformatics can aid rational drug design with minimal 
work in the wet lab. Starting with a single gene sequence, we can determine with strong 
certainty, the protein sequence. From there, we can determine the structure using structure 
prediction techniques. With geometry calculations, we can further resolve the protein‘s surface 
and through molecular simulation determine the force fields surrounding the molecule. Finally 
docking algorithms can provide predictions of the ligands that will bind on the protein surface, 
thus paving the way for the design of a drug specific to that molecule.  
The horizontal axis shows how the influxes of biological data and advances in computer 
technology have broadened the scope of biology. Initially with a pair of proteins, we can make 
comparisons between the between sequences and structures of evolutionary related proteins. 
With more data, algorithms for multiple alignments of several proteins become necessary. Using 
multiple sequences, we can also create phylogenetic trees to trace the evolutionary development 
of the proteins in question. Finally, with the deluge of data we currently face, we need to 
construct large databases to store, view and deconstruct the information. Alignments now 
become more complex, requiring sophisticated scoring schemes and there is enough data to 
compile a genome census – a genomic equivalent of a population census – providing 
comprehensive statistical accounting of protein features in genomes. 
 
Applications of Bioinformatics 
 Database query tools 
 Sequence analysis and molecular Evolution 
 Genome mapping and comparison 
 Gene identification 
 Structure prediction 
 Drug design and drug target identification 
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CADD 
Drug design is the approach of finding drugs by design, based on their biological targets. 
Typically a drug target is a key molecule involved in a particular metabolic or signalling 
pathway that is specific to a disease condition or pathology, or to the infectivity or survival of a 
microbial pathogen. 
Computer-assisted drug design (CADD), also called computer-assisted molecular design 
(CAMD), represents more recent applications of computers as tools in the drug design process. 
In most current applications of CADD, attempts are made to find a ligand (the putative drug) that 
will interact favorably with a receptor that represents the target site. Binding of ligand to the 
receptor may include hydrophobic, electrostatic, and hydrogen-bonding interactions. In addition, 
solvation energies of the ligand and receptor site also are important because partial to complete 
desolvation must occur prior to binding. 
This approach to CADD optimizes the fit of a ligand in a receptor site. However, optimum fit in 
a target site does not guarantee that the desired activity of the drug will be enhanced or that 
undesired side effects will be diminished. Moreover, this approach does not consider the 
pharmacokinetics of the drug. 
Based on the information that is available, one can apply either,  
 Ligand-based drug design is applicable when the structure of the receptor site is 
unknown, but when a series of compounds have been identified that exert the activity of 
interest. To be used most effectively, one should have structurally similar compounds 
with high activity, with no activity, and with a range of intermediate activities.  
 
 Receptor-based drug design incorporates a number of molecular modeling techniques, 
one of which is docking. Docking allows scoring based on force fields, which include 
both van der Waals and electrostatic interactions. These results illustrate the potential for 
docking programs to search objectively for ligands than are complementary to receptor 
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sites, thereby assisting researchers in identifying potential drugs than may be 
considerably different from existing drugs. 
 
 
 
 
Fig 2 Flowchart representing CADD 
Benefits of CADD 
CADD methods and bioinformatics tools offer significant benefits for drug designing programs. 
 Cost Savings. Many biopharmaceutical companies now use computational methods and 
bioinformatics tools to reduce cost burden. Only the most promising experimental lines 
of inquiry can be followed and experimental dead-ends can be avoided early based on the 
results of CADD simulations. 
 Time-to-Market. The predictive power of CADD can help drug research programs 
choose only the most promising drug candidates. By focusing drug research on specific 
lead candidates, biopharmaceutical companies can get drugs to market more quickly.   
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 Insight. One of the non-quantifiable benefits of CADD and the use of bioinformatics 
tools is the deep insight that researchers acquire about drug-receptor interactions. When 
we show researchers new molecular models of their putative drug compounds, their 
protein targets and how the two bind together, they often come up with new ideas on how 
to modify the drug compounds for improved fit.  
 
CADD and Bioinformatics 
Bioinformatics was seen as an emerging field with the potential to significantly improve how 
drugs are found, brought to clinical trials and eventually released to the marketplace. CADD 
methods are heavily dependent on bioinformatics tools, applications and databases. As such, 
there is considerable overlap in CADD research and bioinformatics.  
There are several key areas where bioinformatics supports CADD research.   
 Virtual High-Throughput Screening (vHTS) 
 Sequence Analysis 
 Homology Modeling 
 Similarity Searches  
 Drug Lead Optimization 
 Physicochemical Modeling 
 Drug Bioavailability and Bioactivity 
 
CADD and bioinformatics together are a powerful combination in drug research and 
development. An important challenge for going forward is skilled and efficient management of 
all the bioinformatics resources available to us. Bioinformatics is a field of study which focuses 
on the analysis of large amounts of biological data. The primary focus is the analysis and 
interpretation of complex biological molecules, such as DNA and proteins. Because these 
molecules tend to be very complex, they must be analyzed using computers. 
Molecular biologists often use laboratory-based experiments to analyze a molecule of biological 
interest. Usually, these are molecules of DNA or protein. Both DNA and protein molecules are 
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chains of smaller molecules attached to each other to build a large string-like molecule. Proteins 
are the 'machinery' of biology - they do everything from carrying oxygen through the blood (an 
example of this is Hemoglobin) to movement (an example of this is actin and myosin, which are 
found in muscle fibers). DNA is the primary data source of life. Cells use DNA molecules to 
build proteins, which then perform most biological processes. 
Biology of bioinformatics 
A molecule of DNA is composed of units called nucleic acids. These nuceic acids (there are four 
distinct nucleic acids in DNA) are assembled and stored in the nucleus of a cell. The nucleus is 
basically a storage house of data for the cell. Anything a cell could possibly want, it can build, 
using the information stored in its DNA. When a cell wants to build a protein, it finds the 
appropriate section of DNA, unravels it, and decodes it. This decoding process is how proteins are 
built. Proteins are composed of units called amino acids. There are twenty amino acids that 
combine to form most proteins. Proteins are the 'machinery' of a cell. They can perform many 
functions, like transportation, structural support, movement, metabolism, etc. A basic principle of 
bioinformatics is that everything about these molecules can be inferred from the sequence of 
building blocks (nucleic acids or amino acids) from which the molecule is composed. For 
example: In theory, the structure of a protein (its shape) can be determined by analyzing the 
amino acids that make up the protein. This structure can often be used to deduce its function.  
Computational side of bioinformatics 
Chemists have developed methods for understanding the shape and behavior of small molecules, 
using mathematical analysis. They might use computers (or even just a pencil and paper) to study 
these molecules. As biochemists attempt to study larger and larger molecules, they have found 
that these methods are no longer feasible. It would simply take too much time to determine the 
structure of a large molecule. Using the classical methods, and a very fast computer (to perform 
the mathematics), it would take years, centuries, or even millennia to find the exact structure of a 
very large protein. Because of this, researchers have developed new computational methods to 
approximate the structure (or other properties) of a molecule in a much more reasonable amount 
of time. Protein structure analysis is a very important part of bioinformatics, but it does not 
encompass the field. There are other many studies being done in bioinformatics. Some of the 
questions that are addressed by these studies follow: 
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How does a particular protein bind to another? 
Which proteins will be built given a specific strand of DNA? 
How can DNA analysis predict genetic disorders and diseases? 
How has a biological process or structure changed through evolution? 
What diseases is a person especially vulnerable to, given their genetics? 
All of these questions can be at least partially answered using an extensive analysis of scientific 
data with modern bioinformatics algorithms. 
Drug Design based on Bioinformatics Tools  
Drug design is the approach of finding drugs by design, based on their biological targets. 
Typically a drug target is a key molecule involved in a particular metabolic or signaling pathway 
that is specific to a disease condition or pathology, or to the infectivity or survival of a microbial 
pathogen. Some approaches attempt to stop the functioning of the pathway in the diseased state 
by causing a key molecule to stop functioning. Drugs may be designed that bind to the active 
region and inhibit this key molecule. However these drugs would also have to be designed in such 
a way as not to affect any other important molecules that may be similar in appearance to the key 
molecules. Sequence homologies are often used to identify such risks. Other approaches may be 
to enhance the normal pathway by promoting specific molecules in the normal pathways that may 
have been affected in the diseased state. The structure of the drug molecule that can specifically 
interact with the biomolecules can be modeled using computational tools. These tools can allow a 
drug molecule to be constructed within the biomolecule using knowledge of its structure and the 
nature of its active site. Construction of the drug molecule can be made inside out or outside in 
depending on whether the core or the R-groups are chosen first. However many of these 
approaches are plagued by the practical problems of chemical synthesis. Newer approaches have 
also suggested the use of drug molecules that are large and proteinaceous in nature rather than as 
small molecules. There have also been suggestions to make these using mRNA. Gene silencing 
may also have therapeutical applications.The processes of designing a new drug using 
bioinformatics tools have open a new area of research. However, computational techniques assist 
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one in searching drug target and in designing drug in silico, but it takes long time and money. In 
order to design a new drug one need to follow the following path.  
Identify Target Disease:     
   One needs to know all about the disease and existing or traditional remedies. It is also important 
to look at very similar afflictions and their known treatments. Target identification alone is not 
sufficient in order to achieve a successful treatment of a disease. A real drug needs to be 
developed. This drug must influence the target protein in such a way that it does not interfere with 
normal metabolism. One way to achieve this is to block activity of the protein with a small 
molecule. Bioinformatics methods have been developed to virtually screen the target for 
compounds that bind and inhibit the protein. Another possibility is to find other proteins that 
regulate the activity of the target by binding and forming a complex.  
Study Interesting Compounds:  
                  One needs to identify and study the lead compounds that have some activity against a 
disease. These may be only marginally useful and may have severe side effects. These 
compounds provide a starting point for refinement of the chemical structures.  
Detect the Molecular Bases for Disease:  
                  If it is known that a drug must bind to a particular spot on a particular protein or 
nucleotide then a drug can be tailor made to bind at that site. This is often modeled 
computationally using any of several different techniques. Traditionally, the primary way o f 
determining what compounds would be tested computationally was provided by the researchers' 
understanding of molecular interactions. A second method is the brute force testing of large 
numbers of compounds from a database of available structures.  
Rational drug design techniques: 
                   Unlike the historical method of drug discovery, by trial-and-error testing of chemical 
substances on cultured cells or animals, and matching the apparent effects to treatments, rational 
drug design begins with a knowledge of specific chemical responses in the body or target 
organism, and tailoring combinations of these to fit a treatment profile. Due to the complexity of 
the drug design process two terms of interest are still serendipity and bounded rationality. Those 
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challenges are caused by the large chemical space describing potential new drugs without side-
effects. 
A particular example of rational drug design involves the use of three-dimensional information 
about biomolecules obtained from such techniques as x-ray crystallography and NMR 
spectroscopy. This approach to drug discovery is sometimes referred to as structure-based drug 
design. The first unequivocal example of the application of structure-based drug design leading to 
an approved drug is the carbonic anhydrase inhibitor dorzolamide which was approved in 1995. 
Another important case study in rational drug design is imatinib, a tyrosine kinase inhibitor 
designed specifically for the bcr-abl fusion protein that is characteristic for Philadelphia 
chromosome-positive leukemias (chronic myelogenous leukemia and occasionally acute 
lymphocytic leukemia). Imatinib is substantially different from previous drugs for cancer, as most 
agents of chemotherapy simply target rapidly dividing cells, not differentiating between cancer 
cells and other tissues. 
The activity of a drug at its binding site is one part of the design. Another to take into account is 
the molecule's drug likeness, which summarizes the necessary physical properties for effective 
absorption. One way of estimating drug likeness is Lipinski's Rule of Five. 
Refinement of compounds:  
Once you got a number of lead compounds have been found, computational and laboratory 
techniques have been very successful in refining the molecular structures to give a greater drug 
activity and fewer side effects. This is done both in the laboratory and computationally by 
examining the molecular structures to determine which aspects are responsible for both the drug 
activity and the side effects.  
Quantitative Structure Activity Relationships (QSAR): 
Quantitative structure-activity relationship (QSAR) is the process by which chemical structure is 
quantitatively correlated with a well defined process, such as biological activity or chemical 
reactivity. For example, biological activity can be expressed quantitatively as in the concentration 
of a substance required to give a certain biological response. Additionally, when physiochemical 
properties or structures are expressed by numbers, one can form a mathematical relationship, or 
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quantitative structure-activity relationship, between the two. The mathematical expression can 
then be used to predict the biological response of other chemical structures. 
 
QSAR's most general mathematical form is: 
Activity = f (physiochemical properties and/or structural properties)  
 This computational technique should be used to detect the functional group in your compound in 
order to refine your drug. This can be done using QSAR that consists of computing every possible 
number that can describe a molecule then doing an enormous curve fit to find out which aspects 
of the molecule correlate well with the drug activity or side effect severity. This information can 
then be used to suggest new chemical modifications for synthesis and testing.  
Solubility of Molecule:  
           One need to check whether the target molecule is water soluble or readily soluble in fatty 
tissue will affect what part of the body it becomes concentrated in. The ability to get a drug to the 
correct part of the body is an important factor in its potency. Ideally there is a continual exchange 
of information between the researchers doing QSAR studies, synthesis and testing. These 
techniques are frequently used and often very successful since they do not rely on knowing the 
biological basis of the disease which can be very difficult to determine.  
Drug Testing:  
               Once a drug has been shown to be effective by an initial assay technique, much more 
testing must be done before it can be given to human patients. Animal testing is the primary type 
of testing at this stage. Eventually, the compounds, which are deemed suitable at this stage, are 
sent on to clinical trials. In the clinical trials, additional side effects may be found and human 
dosages are determined.  
Motivation for the study: 
AD (Alzheimer‘s disease) is a progressive, degenerative brain disease. The neuropathology of 
Alzheimer‘s disease (AD) is characterized by several features, including extracellular deposition 
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of amyloid β peptide (Aβ)-containing plaques in the cerebral cortical regions. Aβ (amyloid β) 
peptides, enzymatically derived from the proteolytic processing of the transmembrane APP 
(amyloid precursor protein), are the principal cause of neuronal dysfunction and death in the 
brains of AD patients. Currently, for treat Alzheimer's disease (AD) either acetyl cholinesterase or 
N-methyl-D-aspartate antagonists are available. Acetyl cholinesterase inhibitors have limited 
efficacy because they often have unpleasant side effects. Here we consider the viability of a single 
molecule having the actions of both an AchE inhibitor and histamine H3 receptor antagonist. Both 
histamine H3 receptor antagonists and AchE inhibitors synergist the cholinergic 
neurotransmission in cortex. We have selected histamine H3 receptor antagonist that it raises 
acetylcholine levels mostly in brain as its mode of action will primarily be on the central nervous 
system. And combination of both activities in a single molecule will decrease the unpleasant side 
effect. 
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Literature survey 
ALZHEIMERS DISEASE 
Alzheimer's disease is a progressive, irreversible brain disorder which attacks slowly and steals 
the mind of its victims. It is a  neurodegenerative  disease  characterized  by progressive  
cognitive  deterioration  together with declining  activities  of   daily living    and  
neuropsychiatric symptoms or behavioral changes. It is the most common type of dementia 
(decline in memory and mental abilities 
HISTORY: 
In  1901,  Dr. Alois  Alzheimer, a  German  psychiatrist, interviewed  a  patient  named  Auguste 
D, age 51  suffering  from  declining mental  health. On  November 3,1906, he presented 
Auguste D's case to the 37
th
  Assembly  of Southwest  German  Psychiatrists and  described  the  
neurofibrillary  tangles  and  amyloid  plaques  that   have  come  to be considered  the  hallmark  
of the disease.  Eventually, the  term  Alzheimer's  disease was  adopted  formally  in the  
psychiatric  and  neurological  nomenclature  to  describe  individuals of all ages with the 
characteristic common  symptom  pattern, disease course and neuropathology. 
 
STATISTICS: 
In the United States of  America, AD was the 7th leading  cause of  death  in 2004, with 65,829 
number of deaths (and rising).At over $100 billion per year, AD is the third most costly disease 
in the U.S., after heart  disease and cancer. There are an estimated 24 million people with 
dementia worldwide.  By 2040, it is projected that this figure will have increased to 81 million. 
More than 5 million Americans   are estimated   to have Alzheimer‘s disease. It  is Projected  that  
14.3  million  Americans  will  have  the  disease  by  mid-century: a 350 percent increase from 
2000.The federal government estimates spending approximately $647 million for Alzheimer‘s 
disease research in fiscal year 2005. 
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PROGRESSION OF DISEASE AND SYMPTOMS:  
These images represent a cross-section  of the brain as seen  from  the front. The  cross-section 
on the left represents a brain from a normal individual and the one on the right represents a brain 
with Alzheimer's disease. 
 
                         
 
Fig 3  (a) comparative structure of both healthy brain and AD brain, and Fig (b) is the 
structure of nerve cell with tangles and without tangles.  
 
In Alzheimer's  disease, there  is  an  overall  shrinkage  of   brain tissue. The grooves or   
furrows in  the brain, called sulci (plural of sulcus), are noticeably  widened  and there is 
shrinkage of the gyri (plural of gyrus), the well-developed folds of the brain's outer layer. In 
addition, the ventricles, or chambers  within  the brain that contain cerebrospinal fluid, are 
noticeably enlarged. In  the early stages of  Alzheimer's disease,  short-term  memory begins to 
decline (see box labeled ‗memory') when the cells in the hippocampus, which is part of the 
limbic system, degenerate. The ability to  perform  routine tasks  also declines.  
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As Alzheimer's disease spreads through the cerebral  cortex  (the outer layer of the brain), 
judgment declines, emotional outbursts may occur and language is impaired. Progression of the 
disease leads to the death  of  more nerve cells  and  subsequent  behavior changes,such  as  
wandering  and  agitation. The  ability  to recognize  faces  and to communicate is  completely  
lost  in  the  final  stages. Patients  lose  bowel  and   bladder  control, and eventually  need  
constant  care. This  stage  of  complete  dependency may last for years before the patient dies. 
The average length of time from diagnosis to death is 4 to 8 years, although it can take 20 years 
or more for the disease to run its course.The most striking early symptom is loss of   memory 
(amnesia), which  usually manifests as  minor  forgetfulness  that becomes steadily more 
pronounced with illness progression, with  relative  preservation  of   older   memories. As  the  
disorder  progresses, cognitive (intellectual)   impairment   extends   to   the   domains   of   
language  (aphasia),  skilled movements   (apraxia),  recognition (agnosia),  and   those  functions  
(such  as  decision-making  and  planning)  closely  related  to  the  frontal and temporal lobes of 
the brain as they become disconnected from the limbic system, reflecting extension of the 
underlying pathological process. This pathological process consists principally of neuronal loss 
or atrophy, principally in the temporoparietal cortex, but also in the frontal cortex, together with 
an inflammatory response to the deposition of amyloid plaques and neurofibrillary Tangles One 
of  the  hallmarks  of  Alzheimer's  disease  is the accumulation of amyloid plaques  between  
nerve  cells  (neurons)  in  the  brain. Amyloid  is  a  general  term  for   protein fragments that 
the body produces normally. Beta-amyloid is a fragment of a protein that is  snipped  from  
another  protein  called  amyloid  precursor protein (APP). In a healthy brain,  these protein  
fragments  would  be  broken down  and eliminated. In Alzheimer's disease, the fragments 
accumulate to form hard, insoluble plaques. Neurofibrillary  tangles  consist  of  insoluble  
twisted fibers that are found inside of the brain's  cells. They  primarily  consist  of  a  protein  
called  tau,   which  forms  part of a structure  called  a  microtubule.  The  microtubule  helps  
transport  nutrients  and  other important  substances  from one  part  of  the  nerve  cell  to  
another (the axon is the long thread like  extension  that  conducts  nerve impulses  away from 
the body of a nerve cell, and  dendrites  are  any  of  the  shor t branched thread like  extensions 
that conduct nerve impulses  towards  the nerve cell body. In Alzheimer's disease the tau protein 
is abnormal and the microtubule structures collapse. 
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CAUSES/RISK FACTORS: 
Three  major  competing  hypotheses  exist  to  explain  the  cause  of  the  disease.  
 1)CHOINERGIC HYPOTHESIS: The  oldest, on  which most currently available drug therapies 
are based, is known as the  "cholinergic  hypothesis"  and  suggests  that  AD  is  due  to reduced  
biosynthesis of the neurotransmitter  acetylcholine.  The medications that treat acetylcholine 
deficiency have served to only treat  symptoms of  the disease and have neither halted nor 
reversed it. The cholinergic hypothesis   has   not   maintained widespread support   in the face of 
this evidence,  although   cholingeric   effects  have  been   proposed   to   initiate   large-scale 
aggregation  leading  to  generalized  neuroinflammation. 
2)MISFOLDED AND AGGREGATED PROTEINS: Research  after  2000 includes hypotheses 
centered on the effects  of  the  misfolded  and aggregated  proteins,  amyloid  beta and tau. The 
two positions differ with one stating that the  tau  protein  abnormalities  initiate  the  disease  
cascade, while the other believes that beta  amyloid  deposits  are  the  causative  factor  in  the  
disease .[ The tau  hypothesis is supported  by  the  long-standing  observation  that  deposition  
of amyloid plaques do not correlate well with neuron loss;however, a majority of researchers 
support the alternative hypothesis that amyloid is the primary causative agent.The amyloid  
hypothesis  is  initially compelling  because  the  gene  for the amyloid beta Precursor APP is 
located on chromosome 21, and patients with trisomy 21 - better known as  Down  syndrome -  
who  thus have an extra gene copy almost universally exhibit AD-like disorders  by 40 years  of 
age.The  traditional  formulation of the amyloid hypothesis points to the cytotoxicity  of mature  
aggregated amyloid fibrils, which  are believed to be the toxic form of the protein responsible for 
disrupting the cell's calcium ion homeostasis and thus inducing apoptosis.It   should  be  noted  
further  that  ApoE4, the major genetic  risk  factor for AD, leads to excess  amyloid  build  up  in  
the  brain  before AD symptoms arise. Thus, beta-amyloid deposition  precedes  clinical  
AD.[Another  strong  support  for  the  amyloid hypothesis, which  looks  at  the  beta-amyloid  
as  the  common  initiating  factor for the Alzheimer's disease, is that transgenic mice solely 
expressing a mutant human APP gene develop first diffuse  and  then fibrillar  beta-amyloid 
plaques, associated with neuronal and microglial damage. 
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APP PROCESSING: 
APP   is  a  single-transmembrane   protein  with  a  590-680  aa  long extracellular amino 
terminal domain  and an approximately 55aa cytoplasmic tail which contains intracellular 
trafficking  signals (Fig 1). mRNA  from  the  APP  gene  on  chromosome  21 undergoes 
alternative splicing to yield eight possible isoforms, three of which (the 695, 751 and 770 amino 
acid  isoforms) predominate  in  the brain (2,3). APP695 is the shortest of the three isoforms  and  
is  produced  mainly  in  neurons. Alternatively, APP751, which contains a Kunitz-protease  
inhibitor (KPI)  domain,  and  APP770,  which  contains  both  the   KPI domain  and  an MRC-
OX2 antigen domain, are found mostly in non-neuronal glial cells. All  three  isoforms share the 
same Ab, transmembrane and intracellular domains and are thus  all   potentially  amyloidogenic.  
The normal function of APP is currently unknown, although  in  neurons  it  has  been 
demonstrated to be localized in synapses where is may play a role in neurite extension or 
memory 
 
Fig 4. APP  and  its  proteolytic  products.  Shown is  APP770, the  largest of the three  
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predominant  isoforms  found  in  the brain. Shorter  isoforms are produced by alternative 
splicing  of  mRNA  to  remove  the  OX2 antigen domain (APP751) or both the OX2 and Kunitz 
protease inhibitor domains (APP695). APP can undergo proteolytic processing via 2 pathways. 
Cleavage by a-secretase occurs within the Ab domain and generates the large soluble N- terminal  
APPa   and   a  non-amyloidogenic C - terminal  fragment. A further proteolysis of this fragment 
by g-secretase generates the  non-amyloidogenic  peptide p3. Alternatively,  cleavage of  APP  
by b-secretase occurs at the beginning of the Ab domain and  generates  a   shorter  soluble  N-
terminus,  APPb,  as well as  an  amyloidogenic C-terminal  fragment  (C99). Further  cleavage  
of  this C-terminal  fragment  by g-secretase generates  Ab. Cleavage  by  g-secretase  or multiple 
g-secretases can result in C-terminal heterogeneity of Ab to generate Ab40 and Ab42. 
 3) GENETIC LINKAGE: 
Rare cases of Alzheimer's  are caused by dominant genes that run in families. The  cases often  
have  an  early  age  of onset.  Mutations in presenilin-1 or presenilin-2 genes have been 
documented  in  some  families.  Mutations of  presenilin 1 (PS1)  lead  to  the most aggressive  
form  of  familial  Alzheimer's  disease  (FAD).  Evidence from rodent studies suggests  that  the  
FAD  mutation  of  PS1  results  in  impaired   hippocampal-dependent learning  which   is  
correlated  with   reduced  adult   neurogenesis  in  the dentate  gyrus. 
Mutations  in  the  APP  gene  on  chromosome 21 can also cause early onset 
disease.ThePresenilins have been  identified  as essential  components of  the  proteolytic 
processing machinery that produces beta amyloid peptides through cleavage of APP.Alzheimer's 
disease is definitely linked to the 1st, 14th, and  21
st
  chromosomes, but other linkages  are  
controversial  and not yet confirmed. While some genes predisposing to AD have  been  
identified , such  as  ApoE4  on  chromosome  19, sporadic  AD also involves other risk and 
protective genes still awaiting confirmation 
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RISK FACTORS: 
Age : Alzheimer's  usually  affects  people  older  than  65,  but  can,  rarely,  affect  those 
younger  than  40.  Less   than 5 percent  of  people  between 65 and 74 have Alzheimer's.   For   
people  85 and older, that number jumps to nearly 50 percent.  
Heredity: Your  risk of  developing  Alzheimer's  appears  to  be slightly higher if a first- degree  
relative  —  parent,  sister  or  brother  — has  the  disease.  Although  the genetic mechanisms of 
Alzheimer's among families remain largely unexplained, researchers have identified  a  few  
genetic mutations that greatly increase risk in some familiesfew genetic mutations that greatly 
increase risk in some families.   
Sex:Women  are  more  likely  than  men  are  to develop the disease, in part because they live 
longer.  
Heredity:The  same  factors that  put  you  at  risk  of  heart disease, such   as high  blood 
pressure  and  high  cholesterol,  may  also  increase  the  likelihood   that   you'll  develop 
Alzheimer's  disease . Poorly controlled diabetes is another risk factor. And keeping your body 
fit isn't your only concern — you've got to exercise your mind as well. Some studies have  
suggested  that  remaining  mentally  active  throughout your life, especially in your years, 
reduces the risk of Alzheimer's disease.  
Education levels: Studies have  found  an association between less education and the risk of  
Alzheimer's.  Some  researchers  theorize  that  the  more you use your brain, the more synapses  
you  create ,  which  provides  a  greater  reserve as you age. It remains unclear, however, 
whether less education and less mental activity create a risk of Alzheimer's or if it's  simply  
harder to detect Alzheimer's in people who exercise their minds frequently or who have more 
education.  
Toxicity: One   long-standing   theory   is  that  overexposure  to  certain  trace  metals  or 
chemicals  may  cause  Alzheimer's.  For a   time, aluminum seemed  a  likely candidate, because  
some  people  with  Alzheimer's have deposits of aluminum in their brains. After many years of 
studies, however, no one has been able to link aluminum exposure directly to Alzheimer's. At 
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this point, there's no evidence that any particular substance increases a person's risk of 
Alzheimer's.  
Head injury: The observation that some ex-boxers eventually develop dementia suggests that 
serious traumatic injury to the head (for example, a concussion with a  prolonged loss of 
consciousness)  may be a risk factor for Alzheimer's. Several studies indicate a definite link 
between the two, but others show no link.  
Hormone replacement therapy: 
The   exact   role   hormone   replacement   therapy   may   play   in the  development   of  
dementia   isn't  yet  clear. Throughout the 1980s and '90s, evidence  seemed to show that 
estrogen supplements given after menopause could reduce the  risk  of dementia. But results 
from the large-scale Women's Health Initiative Memory Study indicated   an  increased  risk  of  
dementia for women taking estrogen after age 65. The verdict  is  not  yet  in  on whether 
estrogen affects the risk of dementia if given at an earlier age. 
 
TESTS/DIAGONOSIS: 
No single test can detect Alzheimer‘s.  Instead, the disease is diagnosed by symptoms, findings 
on neurologic examination, and results from diagnostic tests. These tests help exclude other 
conditions that might cause the signs and symptoms. A  diagnosis  of  Alzheimer's  may  be  " 
probable ,"  meaning   that  other  causes  of  the symptoms  have  been   ruled  out and the  most  
likely  cause  is Alzheimer's disease. First, the patient will have a complete  physical exam, along  
with  a detailed history of symptoms   and  medical  history,  including medications. Examination   
by   neurology specialists  will  help  identify  signs of  Parkinson's  disease ,  strokes , tumors  
and  other medical conditions  that  ma  impair  memory and thinking, as well as physical  
function. Tests may include: 
Mental status and neuropsychological assessments: 
To determine which thinking and memory functions may be affected and to what degree, the 
patient will be asked questions to measure cognitive functions for attention, learning, recall, 
language and visuospatial abilities. The tests  are compared to the tests of other patients of 
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similar age and education. The  patient  and  people  familiar  with  the patient will be 
interviewed about the patient's emotional  state  and  day-to-day routines . They will also be 
asked about possible alcohol or drug abuse, head trauma and other causes for memory loss. 
Family members or close friends can provide valuable information about how the patient's 
behavior and personality have changed. 
Psychiatric assessments: 
In addition, the patient may have a psychiatric assessment to uncover possible depression or 
other mental illness. 
Blood tests: 
The   patient's   blood   will be checked for infections or conditions such   as   vitamin deficiency, 
anemia, medication levels, disorders of the thyroid, kidneys or liver, and other factors that can 
cause memory loss. 
Brain imaging: 
Internal images of the brain help detect strokes, tumors or other conditions that may have 
affected the brain. Brain images can show changes to structures I in the brain that are associated 
with memory, such as the hippocampus. Various brain imaging techniques are 
Computed tomography (CT scan): 
In this test, an X-ray machine rapidly rotates around the brain while taking a series of thin X-ray 
beams that produce two-dimensional images. 
Magnetic resonance imaging (MRI):  
 This test uses powerful magnets and radio waves to produce a detailed, three-dimensional view 
of the brain. Most patients are asked to undergo an  MRI  scan.  Depending on the individual, 
another scan technique may be performed. 
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Positive emission tomography (PET) or Single-photon emission computerized tomography 
(SPECT): 
These two fairly new techniques may be needed for clinical-related or research-related study.  
For both tests, a small amount of radioactive material is injected into the patient and emission   
detectors are placed on   the brain.  PET provides visual images of brain activity.  SPECT is used 
to measure blood flow to various regions of the brain. 
Other tests: 
Other   tests   that   sometimes  provide   important   diagnostic   information  include  the 
Electroencephalogram  (EEG), electromyogram  (EMG ),  urine  tests ,  and   tests   on 
cerebrospinal   fluid  (CSF)  obtained by  a  lumbar  puncture. Physicians discuss with the patient 
and family which tests are most appropriate to establish the correct diagnosis 
RISK REDUCERS: 
Intellectual stimulation (e.g., playing chess or doing crosswords)Regular physical exercise 
Regular social interaction A Mediterranean diet with fruits and vegetables and low in saturated 
fat, supplemented in  particular with: B vitamins Omega-3 fatty acids, especially 
Docosahexaenoic acid Fruit and vegetable juice High doses of the antioxidant Vitamin E (in 
combination with vitamin C) seem to reduce Alzheimer's  risk  in  cross sectional studies  but  
not in  a randomized trial and so are not currently  a  recommended  preventive  measure  
because of observed increases in overall mortality Cholesterol-lowering drugs (statins) reduce 
Alzheimer's risk  in  observational studies but so far not in randomized controlled trials Female  
Hormone  replacement  therapy  is  no  longer thought to prevent dementia based on data from 
the Women's Health Initiative Long - term   usage  of   non-steroidal  anti-inflammatory    drugs   
used  to  reduce   joint inflammation  and  pain,  are  associated  with  a  reduced  likelihood  of  
developing AD, according  to some  observational studies. The risks appear to outweigh the 
drugs' benefit as a method of primary prevention 
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Alzheimer's disease Medications 
Currently, there is no cure for Alzheimer's disease (AD). However, there are medications that 
can help control its symptoms. In addition, treatments are also available to help manage 
agitation, depression or psychotic symptoms (hallucinations or delusions) which may occur as 
the disease progresses.  
1. Acetyl-cholinesterase inhibitors (AchE inhibitors)  
Cholinesterase inhibitors slow the metabolic breakdown of acetylcholine, and make more of this 
chemical available for communication between cells. This helps in delaying the progression of 
cognitive impairment and can show efficacy for some patients in the early to middle stages of 
AD. All the four treatments are approved for mild to moderate symptoms of AD.  In 2006, the 
FDA for the treatment of severe AD symptoms approved one drug Aricept®.  The four FDA-
approved cholinesterase inhibitors are: 
 Razadyne® (galantamine)  
 Exelon® (rivastigmine)  
 Aricept® (donepezil)  
 Cognex® (tacrine)  
 
2.        Nicotinic acetylcholine receptors (nAChRs) 
Neuronal nicotinic acetylcholine receptors (nAChRs) are  found in the central and peripheral 
nervous systems that regulate number of diseases, including Alzheimer‘s discussed and 
investigated.(21)The nicotinic acetylcholine receptors (nAChRs) structurally it is  pentameric 
and(22,23) Nicotine/acetylcholine binds to the receptor and depolarization  occur, nAChR 
subtypes are found in different locations of the central and peripheral nervous system and the 
α4β2 and α4β4 subtypes appear to play a role in neurodegeneration(specially Alzheimer‘s 
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disease (AD and Attention Deficit Hyperactivity Disorder (ADHD).) Thus, the therapeutic 
potential of nAChR agonists, such as nicotine, in Alzheimer‘s, Parkinson‘s disease, Tourette‘s 
syndrome, and pain is being recognized Various  analogues of nicotine(pyridine and pyrrolidine) 
were synthesized And one class agonists has entered clinical trials to treat the Alzheimer disease 
from the Abbott Laboratories(ABT 418) (.23) 
 
3. N-methyl,D-aspartate inhibitors (NMDA) 
Persistent activation of central nervous system‘s NMDA receptors by the excitatory amino acid 
glutamate has been hypothesized to contribute to the symptomatology of AD. Thus inhibiting 
this receptor might improve symptoms in AD patients. Namenda® (memantine) was the first 
NMDA inhibitor to be approved by FDA .It protects the brain nerve cells by inhibiting the 
release of glutamate (neurotransmitter).Namenda binds to NMDA receptor and decrease the 
calcium to flow into the cell, which in turn decease the cell degeneration. Namenda causes 
minor side effect like dizziness, confusion, headache and constipation that are well-tolerated.  
 
 
4. Treatment of anxiety, depression & psychosis 
Often, in case of mild to severe Alzheimer‘s disease person often experiences depression, 
agitation, paranoid thoughts, delusions and hallucinations. The individual may be unable to 
communicate, be frustrated by his or her limitations, misunderstand what is happening or simply 
forget how to respond appropriately. Some common drugs currently in use are fluoxetine, 
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paroxetine, buspirone to treat depression and anxiety if the later condition becomes so severe that 
the patient becomes danger for him/herself. 
 
 
5. A-beta deposit antagonists (metal chelators) 
Increasing evidence shows that several metal species such as aluminum, iron, zinc, and copper 
induce A-βeta aggregation and neurotoxicity in the AD brain by producing reactive oxygen 
species. In vitro studies have been done, and metal binding ligands have also been employed. 
Metal chelators like Desferrioxamine, MPAC and clioquinol, have shown efficacy in vitro cell 
and animal models of AD patients. AD patients have elevated levels of copper and zinc in the 
neocortex. The transition metals are particularly concentrated in neuritic plaques and potentiate 
A-βeta aggregation and neurotoxicity in vitro. Clioquinol chelates with copper and zinc in 
postemortem AD brains and solubilizes A-βeta. Thus, A-βeta accumulation in the brain may be 
significantly reduced by treatment with Clioquinol as a therapeutic agent. Crystal structure 
analysis confirms the coordination chemistry behind clioquinol's possible role as metal chelator.   
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6. Antioxidants 
 From in-vitro study suggests that due to metal binding generation of reactive oxygen species 
which is responsible for neuodegeneration. Thus, antioxidant plays important role in reduce 
oxidative injury and prove beneficial in retarding or preventing the onset and progression of AD 
in patients. An extract from Antioxidant like Ginkgo biloba (Egb761), melatonin, idebenone, 
dehydroevodiamine hydrochloride, manganese porphyrin, salen and vitamin E, was examined to 
assess efficacy and safety in patients with AD  showed improvement on the Alzheimer's Disease. 
Melatonin also has antiamyloidogenic activities. Dehydroevodiamine Hydrochloride (DHED) 
extracted from Evodia rutaecarpa. Results showed that DHED also protects neurons against 
glutamate and hydrogen peroxide. DHED decreases reactive oxygen species production and cell 
death suggesting that DHED might be useful in treatment of AD, vascular dementia and stroke. 
DHED is currently under clinical studies so that they can be in future used as a potential 
candidate for AD treatment. 
 
 
7. Monoamine Oxidase Inhibitors (MAO-inhibitors) 
Selegiline  
Research shows that when certain MAO inhibitors such as selegiline are used, they delayed the 
deterioration related to the Alzheimer‘s disease. The effect was also seen with vitamin E or a 
combination of both. These drugs, although, doesn‘t have significant effect on cognitive ability. 
Rasagiline and TVP1022     
N-propargyl-1(R)-aminoindan, rasagiline & its optical isomer TVP1022 are selective irreversible 
inhibitors for MAO. They are structurely very similar to selegiline. Both compounds have 
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similar neuroprotective activities with neuronal cell cultures, which is associated to the 
propargylamine functionality. However, rasagiline inhibits MAO-B to a much greater extent. 
 
8. Non-steroidal Anti-inflammatory Drugs (NSAIDs) 
 Inflammation around around the Abeta plaques causes the destruction of neuron is thought to be 
a major factor in the pathogenesis of AD. NSAIDs decreases the inflammation by inhibiting the 
cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX 2), which are responsible for the 
oxidation of arachidonic acid to prostaglandins. Individuals study shows that regular use of using 
conventional NSAIDs decreased incidence of AD and Act as neuroprotective.. 
 
Role of histamine-3 receptor in prospect of Alzheimer’s  
The histamine receptor are broadly classify in to  four receptor subtypes H1, H2,H3, and H4, that 
mediate the diverse biological effects (Brown et al., 2001). Like all histamine receptors the H3 
receptor is a G-protein coupled receptor. H3 receptors are widely expressed in the mammalian 
brain, particularly in areas involved in cognitive processes and arousal, such as the cerebral 
cortex, hippocampus, basal ganglia, and hypothalamus (Martinez-Mir et al., 1990; Pollard et 
al.,1993). Activation of H3 autoreceptors results in the inhibition of histamine synthesis and  
heteroreceptors leads to the inhibition of release of other neurotransmitters such as acetylcholine, 
noradrenaline, dopamine, and 5-HT from nonhistaminergic neurons 
(Blandina et al., 1996; Schlicker and Kathmann, 1998; Brown et al., 2001).Conversely, blockade 
of H3 receptors with selective antagonists can increase the release of neurotransmitters involved 
in cognitive processes (Fox et al., 2005). Selective H3 antagonists have been shown to improve 
performance in a diverse range of rodent cognition paradigms, including object recognition.  
These observations provide the first evidence of a regulatory role of histamine H3 receptors on 
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cortical acetylcholine release in vivo. Moreover, they suggest a role for histamine in learning and 
memory and may have implications for the treatment of degenerative disorders associated with 
impaired cholinergic function.The presynaptic inhibitor-histamine H3 receptor, when activated 
decreases the release of acetylcholine from cholinergic neurons. This has been shown both in the 
gastrointestinal and central nervous system. Consequently, when a histamine h3 receptor 
antagonist is present, an increase release of acetylcholine is observed.thus; both mechanisms 
contribute to the same neurochemical end result (increased synaptic levels of acetylcholine) in 
different ways. The histamine h3 receptor antagonists increase the amount of acetylcholine 
molecules entering the synaptic space, and AchE inhibitors entering the synaptic space , and 
AchE inhibitors prolong their survival time and hence the likelihood of their interacting with a 
postsynaptic cholinergic neurotransmitter and eliciting a biological effect. 
In order to achieve a specific, cognition-enhancing level of cholinergic neurotransmission, a 
lower dose of an AchE inhibitor-histamine H3 receptor antagonist compound will likely be 
required than of either an AchE inhibitor or histamine H3 receptor antagonist alone, a 
combination molecule will have a higher potentcy for increasing acetylcholine levels than either 
an AchE inhibitor alone or histamine h3 receptor antagonist alone. It is likely reduced compound 
requirements for efficacy will then improve the side effect profile.  
 
We describe herein the molecular modeling efforts that lead to the identification of an AchE 
inhibitor-histamine H3 receptor antagonist. The use of available crystal structure information of 
AchE receptor, homology model  structure of H3 receptor based on bacterial rhodopsin crystal 
structure, pharmacophore modeling, QSAR, rigid docking and molecular dynamic simulation. 
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CHAPTER 3 
 
 
 
 
 
 
 
 
 
 
 
TOOLS FOR STUDY 
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TOOLS FOR STUDY: 
3.1Sequence alignments Tools 
Sequence alignments provide a powerful way to compare novel sequences with previously 
characterized genes. Both functional and evolutionary information can be inferred from well 
designed queries and alignments. BLAST (Basic Local Alignment Search Tool), provides a 
method for rapid searching of nucleotide and protein databases. Since the BLAST algorithm 
detects local as well as global alignments, regions of similarity embedded in otherwise unrelated 
proteins can be detected. Both types of similarity may provide important clues to the function of 
uncharacterized proteins. 
 
3.2. Homology modelling 
 
3.2.1 On Line Homology Modelling Softwares 
Swiss model (www.expasy.ch/swissmod/ SWISS-MODEL.html) is a fully automated protein 
structure Homology Modeling server. It has a first approach mode that helps performs 
Homology Modeling. The user has to enter his / her email id and input the protein sequence in 
Fasta format. It allows the user to choose the BLAST limit for template selection. It can search 
the pdb file from the pdb database with the user providing the name of the pdb file or the user 
can upload his / her own pdb file. The output file is a pdb file that is returned to the user's  email 
address. The result can be forwarded by Swiss Model to PHD Secondary structure prediction at 
Columbia University and Fold Recognition Server (3D-pssm) of the ICRF. Swiss Model 
however does not accept the sequences for homology modelling when similarity is less than 
25%[23]. 
Geno3D (http://geno3d-pbil.ibcp.fr) performs Comparative protein structure Modeling by spatial 
restraints (distances and dihedral) satisfaction. Geno3D is most frequently used for Homology or 
Comparative protein structure Modeling.Geno3d accepts input similar to Fasta format but only 
the one letter code has to be used. The result is obtained in the pdb format that can be viewed in 
any Molecular Modeling software.Geno3d offers many other features, it allows the user to select 
PDB entries as templates for Molecular Modeling after a 3 step iterative PSI BLAST. It presents 
the output for each template, along with the secondary structure prediction, displays percent of 
agreement in secondary structure and repartition of information from template on query 
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sequence. The output link is sent to the user's email address. It also notifies the user when it's 
server begins the Homology Modeling. It has an option where the user can decide how many 
models to generate. The main idea behind having more than one model generated is that the user 
may have a better flexibility and understanding. It also returns a superimposed pdb file which has 
the models superimposed on each other. This is one of the good points in Geno3d as it allows us 
to compare the various models generated in one window. All the results obtained can be 
downloaded as a archive.tar.Z that can be opened in WinZip in windows and in UNIX or Linux 
platforms. So the user does not have to save results in webpage effect or in a document file. It 
also displays the Ramachandran plot in the result[24]. 
CPHmodels Automated neural-network based protein modeling server 
(Http://www.cbs.dtu.dk/services/CPHmodels/). CPHmodels is a collection of databases and 
methods developed to predict protein structure. It performs prediction of protein structure using 
Comparative Modeling. It does not accept more than 900 amino acids in the input sequence. The 
sequences are kept confidential and are deleted after processing. This program did not give me 
appropriate results. The error it displayed was similar to the one displayed by Swiss Model. 
3.2.2 Offline Homology Modelling Software: 
MODELLER is used for homology or comparative modeling of protein three-dimensional 
structures. It is built in FORTRAN. It will runs on python script file commands. Modeller is 
most frequently used for homology or comparative protein structure modeling. Modeller helps 
determine the spatial restraints from the templates. It generates a number of 3D models of the 
sequence you submit satisfying the template restraints. MODELLER automatically calculate a 
full-atom model. MODELLER models protein 3D structure keeping in the constraints of spatial 
restraints. The restraints can be derived from a number of different sources. These include NMR 
experiments (NMR refinement),cross-linking experiments, fluorescence spectroscopy, rules of 
secondary structure packing (combinatorial modeling),image reconstruction in electron 
microscopy, homologous structures (comparative modeling),site-directed mutagenesis, residue-
residue and atom-atom potentials of mean force, etc. Modeller is not an automated homology 
modelling tool. 
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It is a very specific program. Any error in the format of the sequence alignment prevents the 
modeller from performing Homology Modeling. The program is very specific about the 
extension names of the file formats used for Homology Modeling. It is a very reliable program 
and it allows the user to specify what he wants in the end result. Modeller runs on platforms like 
Win XP, Linux, Sun Solaris and Macintosh.  
Deep View - Swiss-PdbViewer is an application that provides a user friendly interface allowing 
to analyze several proteins at the same time. The proteins can be superimposed in order to 
deduce structural alignments and compare their active sites or any other relevant parts. Amino 
acid mutations, H-bonds, angles and distances between atoms are easy to obtain thanks to the 
intuitive graphic and menu interface. DeepView - Swiss-PdbViewer has been developped by 
Nicolas Guex (GlaxoSmithKline R&D). Swiss-PdbViewer is tightly linked to SWISS-MODEL, 
an automated homology modeling server developed within the Swiss Institute of Bioinformatics 
(SIB) at the Structural Bioinformatics Group at the Biozentrum in Basel[27]. 
3.2.3  Structure Analysis and Verification Server 
PROCHEK Checks the stereochemical quality of a protein structure by analyzing residue-by-
residue geometry and overall structure geometry. It is tell about: Covalent geometry, Planarity, 
Dihedral angles, Chirality, Non-bonded interactions[28]. 
WHAT_CHEK derived from a subset of protein verification tools from the WHATIF program; 
this does extensive checking of many sterochemical parameters of the residues in the model[29]. 
DOPE: The DOPE model score is designed for selecting the best structure from a collection of 
models built by MODELLER. DOPE uses the standard MODELLER energy function. 
ERRAT is a protein structure verification algorithm that is especially well-suited for evaluating 
the progress of crystallographic model building and refinement. The program works by 
analyzing the statistics of non-bonded interactions between different atom types. A single output 
plot is produced that gives the value of the error function vs. position of a 9-residue sliding 
window. By comparision with statistics from highly refined structures, the error values have 
been calibrated to give confidence limits. ERRAT will give an ―overall quality factor‖ and if it is 
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a   high 90% range protein structure is good. This is extremely useful in making decisions about 
reliability[30]. 
VERIFY_3D determines the compatibility of an atomic model (3D) with its own amino acid 
sequence (1D) by assigned a structural class based on its location and environment (alpha, beta, 
loop, polar, nonpolar etc) and comparing the results to good structures.Then a database generated 
from vetted good structures is used to obtain a score for each of the 20 amino acids in this 
structural class. For each residue, the scores of a sliding 21-residue window (from -10 to +10) are 
added and plotted[31]. 
PROVE Calculates the volumes of atoms in macromolecules using an algorithm which treats the 
atoms like hard spheres and calculates a statistical Z-score deviation for the model from highly 
resolved (2.0 Å or better) and refined (R-factor of 0.2 or better) PDB-deposited structures[32]. 
3.6 Docking Tools 
Autodock 4.0  
The introduction of AutoDock 4 comprises three major improvements: 
1. The docking results are more accurate and reliable.  
2. It can optionally model flexibility in the target macromolecule.  
3. It enables AutoDock's use in evaluating protein-protein interactions. 
AutoDock 4 offers many new features and improvements over previous versions. The most 
significant is that it models flexible side chains in the protein. We can get both the 3D structure 
and the inhibition constants. 
AutoDock4 scoring functions are van der Waals forces, Hydrogen Bonding, Electrostatics, 
Desolvation, Torsional. 
Binding energy=Intermolecular energy+ Torsional energy  
∆Gbind = ∆Gvdw + ∆Gele.  + ∆GH-bond + ∆G desolv +∆Gtors  
 Here ∆G=change in free energy 
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The aim of this part is to re-dock the ligand present in the crystal structure of a protein using an 
automated docking suite called 'AutoDock'. The GUI for AutoDock is AutoDockTools (ADT), 
which was used to perform the entire docking task. More information is available on the 
AutoDock suite homepage http://www.scripps.edu/mb/olson/doc/autodock/.After preparing the 
protein and ligand files through chimera, all files must be transferred to the Autodock directory. 
Further modification to the protein and ligand, something like fixing the torsion residues ec are 
made and the files are saved in PDBQT format. The grid box is setted on the protein. After 
Autodock completes, the docking results are saved in a file named ―dlg‖ in the directory. The 
conformation with the lowest docking energy is ranked best by AutoDock. One can see the 
clusters of docked conformations based on Binding energies by Opening and scrolling down the 
―dlg‖ file until we find 'CLUSTERING HISTOGRAM'.  Make a note of the cluster rank, lowest 
docked energy, number of conf. in the cluster.AutoDock is used to perform computational 
molecular docking of small molecules to proteins, DNA, RNA and other important 
macromolecules, by treating the ligand and selected parts of the target as conformationally 
flexible. It uses a scoring function based on the AMBER force field, and estimates the free 
energy of binding of a ligand to its target. Novel hybrid global-local evolutionary algorithms are 
used to search the phase space of the ligand-macromolecule system. 
 
3.7 GOLD 
GOLD (Genetic Optimisation for Ligand Docking) is a genetic algorithm for docking flexible 
ligands into protein binding sites. GOLD provides all the functionality required for docking 
ligands into protein binding sites from prepared input files. GOLD offers a choice of scoring 
functions, GoldScore, ChemScore, Astex Statistical Potential (ASP) and User Defined Score 
which allows users to modify an existing function or implement their own scoring function. 
The GOLD fitness function (Goldscore) is made up of four components: 
o protein-ligand hydrogen bond energy (external H-bond) 
o protein-ligand van der Waals (vdw) energy (external vdw) 
o ligand internal vdw energy (internal vdw) 
o ligand torsional strain energy (internal torsion) 
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oOptionally, a fifth component, ligand intramolecular hydrogen bond energy (internal H-bond), 
may be added. output files will contain a single internal energy term S(int) which is the sum of 
the internal torsion and internal vdw terms. 
S(int)= internal torsion+ internal vdw 
The fitness score is taken as the negative of the sum of the component energy terms, so that 
larger fitness scores are better. If any constraints have been specified, then an additional 
constraint scoring contribution S(con) will be made to the final fitness score. Similarly, when 
docking covalently bound ligands a covalent term S(cov) will be present. 
The ChemScore function was trained by regression against measured affinity data. ChemScore 
estimates the total free energy change that occurs on ligand binding as: 
         ?Gbind = ?G0  + ?GH-bond + ?Gmetal + ?Glipo +?Grot 
The final ChemScore value is obtained by adding in a clash penalty and internal torsion terms, 
which militate against close contacts in docking and poor internal conformations. Covalent and 
constraint scores may also be included. 
Chemscore = ?Gbinding + Pclash + cinternalPinternal + (ccovalentPcovalent +Pconstraint ) 
 
3.8 QSAR : 
The Quantitative Structure Activity Relationship (QSAR) paradigm is based on the assumption 
that there is an underlying relationship between the molecular structure and biological activity. 
On this assumption QSAR attempts to establish a correlation between various molecular 
properties of a set of molecules with their experimentally known biological activity. 
 
There are two main objectives for the development of QSAR: 
1) Development of predictive and robust QSAR, with a specified chemical domain, for 
prediction of activity of untested molecules. 
2) It acts as an informative tool by extracting significant patterns in descriptors related to the 
measured biological activity leading to understanding of mechanisms of given biological 
activity. This could help in suggesting design of novel molecules with improved activity profile. 
 
QSAR's most general mathematical form is: Activity = f (physiochemical and/or structural 
properties) 
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Data Requirement and Handling: Biological Activity 
For QSAR analysis, a dataset of a series of synthesized molecules tested for its desired biological 
activity is required. For a QSAR to bevalid and reliable, the activity of all of the chemicals 
covered must be elicited by a common mechanism. The quality of the model is totally dependent 
on the quality of the experimental data used for building the model.  
Biological activity can be of two types: 
1) Continuous Response: MEC, IC50, ED50, % inhibition 
2) Categorical Response: Active/Inactive 
In order to have confidence in QSAR analysis, biological data of at least 20 molecules is 
recommended: 
1) Preferably tested in the same lab and by the same biological assay method. 
2) With wide range and uniform distribution of the activity data. 
3) Activity should well-defined in terms of either real number (continuous response, and cannot 
be e.g. >1000 or <1000) or in a particular class (categorical response). 
 
3.8.1 Molecular Descriptors 
Molecular descriptors can be defined as a numerical representation of chemical information 
encoded within a molecular structure via mathematical procedure. Type of QSAR is based on the 
dimensionality of molecular descriptors used: 
1. 0D- These are descriptors derived from molecular formula e.g. molecular weight, number 
and type of atoms etc. 
2. 1D- A substructure list representation of a molecule can be considered as a one-
dimensional (1D) molecular representation and consists of a list of molecular fragments 
(e.g. functional groups, rings, bonds, substituent etc.). 
3. 2D- A molecular graph contains topological or two dimensional (2D) information. It 
describes how the atoms are bonded in a molecule, both the type of bonding and the 
interaction of particular atoms (e.g. total path count, molecular connectivity indices etc.). 
4. 3D- These are calculated starting from a geometrical or 3D representation of a molecule. 
These descriptors include molecular surface, molecular volume and other geometrical 
properties. There are different types of 3D descriptors e.g. electronic, steric, shape etc. 
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5. 4D-In addition to the 3D descriptors the 4th dimension is generally in terms of different 
conformations or any other experimental condition. 
 
3.8.2 Selection of training and test set: 
QSAR models are used increasingly to screen chemical databases and/or virtual chemical 
libraries for potentially bioactive molecules. These developments emphasize the importance of 
rigorous model validation to ensure that the models have both the ability to explain the variance 
in the biological activity (internal validation) and also the acceptable predictive power (external 
validation).For model validation the dataset is required to be divided into training set (for 
building the QSAR model) and test set (for examining its predictive ability). For any QSAR 
model, it is of crucial importance that the training set selected to calibrate the model exhibits a 
well balanced distribution and contains representative molecules. 
 
Following are the methods for division of the dataset into training and test set: 
1) Manual Selection: This is done by visualizing the variation in the chemical and 
biological space of the given dataset. 
2) Random Selection: This method creates training and test set by random distribution. 
3) Sphere Exclusion Method: This is a rational method for creation of training and test set. It 
ensures that the points in the both the sets are uniformly distributed w.r.t. chemical and 
biological space. 
4) Others: 
a) Experimental Design: full factorial, fractional factorial etc. 
b) Onion Design 
c) Cluster Analysis 
d) Principal Component Analysis 
e) Self Organizing Maps (SOM) 
 
3.8.3 Variable selection methods: 
There are a hundreds of molecular descriptors available for building a QSAR model. Not all of 
the molecular descriptors are important in determining the biological activity, and hence to find 
the optimal subset of the descriptors which plays an important role in determining activity, a 
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variable selection method is required. The variable selection method could be divided mainly 
into two categories: 
1) Systematic variable selection: These methods add and/or delete a descriptor in steps one-by-
one in a model. 
a) Stepwise forward 
b) Stepwise forward-backward 
c) Stepwise backward 
2) Stochastic variable selection: These methods are based on simulation of various physical or 
biological processes. These methods creates model starting from randomly generated model(s) 
and later modifying these model(s) by using different process operator(s) (e.g. perturbation, 
crossover etc.) to get better model(s). 
a) Simulated Annealing 
b) Genetic/Evolutionary Algorithms 
c) Modified Particle Swarm Optimization 
d) Artificial Ant Colony System 
 
3.8.4 Statistical Methods: 
• A suitable statistical method coupled with a variable selection method allows analyses of this 
data in order to establish a QSAR model with the subset of descriptors that are most statistically 
significant in determining the biological activity. 
• The statistical methods can be broadly divided into two : linear and non-linear methods. In 
statistics a correlation is established between dependent variable(s) (biological activity) and 
independent variable(s) (molecular descriptors).The linear 
method fits a line between the selected descriptors and activity as compared to non-linear method 
which fits a curve between 
the selected descriptors and activity. 
• The statistical method to build QSAR model is decided based on the type of biological activity 
data. Following are few commonly used statistical methods: 
Categorical Dependent Variable 
a) Discriminant analysis 
b) Logistic regression 
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c) k-Nearest Neighbor classification 
d) Decision Trees 
e) SIMCA 
Continuous Dependent Variable 
a) Multiple Regression 
b) Principal Component Regression 
c) Continuum Regression 
d) Partial Least Squares Regression 
e) Canonical Correlation Analysis 
f ) k-Nearest Neighbor method 
g) Neural Networks 
Commonly used: 
3.8.5 Interpretation of Model: 
• Multiple regression is widely used method for building QSAR model. It is simple to interpret a 
regression model, in which contribution of each descriptor could be seen by the magnitude and 
sign of its regression coefficient. 
• A descriptor coefficient magnitude shows its relative contribution w.r.t other descriptors and 
sign indicates whether it is directly (+) or inversely (-) proportional to the activity. 
3.9  Molecular Dynamics Simulation 
Although normally represented as static structures, molecules such as lysozyme are in fact dynamic. Most 
experimental properties, for example, measure a time average or an ensemble average over the range of 
possible configurations the molecule can adopt. One way to investigate the range of accessible 
configurations is to simulate the motions or dynamics of a molecule numerically. This can be done by 
computing a trajectory, a series of molecular configurations as a function of time, by the simultaneous 
integration of Newton's equations of motion 
  dri(t)   =     vi(t)          (eqn. 1) 
    dt 
and 
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  dvi(t)   =      Fi(t)         (eqn. 2) 
   dt                mi 
for all atoms (i = 1, 2 ,...,N) of the molecular system. The atomic coordinates, r, and the velocity, 
v, of atom, i, with mass, mi, thus become functions of time. The force Fi exerted on atom i by the 
other atoms in the system is given by the negative gradient of the potential energy function V 
which in turn depends on the coordinates of all N atoms in the system: 
 Fi(t)  =  -δV (r1(t),r2(t),…,rN(t))            (eqn. 3) 
                            δri(t) 
For small time steps δt, eqn. (2) can be approximated by 
  Vi(t+∆t/2) =  vi(t-∆t/2) + Fi(t) . ∆t        (eqn. 4) 
                                            mi 
and eqn. (1) likewise by 
ri(t+∆t) = ri(t) + vi(t+∆t/2)∆t    (eqn. 5) 
 Thus a 100 ps (10
-10
 seconds) molecular dynamics simulation involves 10
5
 to 10
4
 integration 
steps. Even using the fastest computers only very rapid molecular processes can be simulated at 
an atomic level. As with any aspect of modelling, the accuracy of the predicted dynamics will 
depend on the validity of the underlying assumptions of the model. In this case the model is 
essentially defined by the force field that is used. For this exercise we will be using the 
GROMOS96 empirical force field. 
This technique is commonly referred to as Molecular Dynamics (MD). A detailed explanation of 
the concepts behind this numerical technique can be found at 
http://www.fisica.uniud.it/~ercolessi/md/md.  
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Factors that govern the outcome of MD simulations are:  
o choice of the degrees of freedom  
o force field parameters  
o treatment of non-bonded interactions  
o salvation effects  
o boundary conditions  
o treatment of temperature and pressure  
o integration time step  
o starting configuration  
As with any aspect of modeling, the accuracy of the predicted dynamics will depend on the 
validity of the underlying assumptions of the model. In this case this is essentially defined by the 
model for the intermolecular interactions (or potential energy) used. That model is a 
mathematical function (force field) that describes how the value for the potential energy depends 
on the spatial arrangement of all the atoms. 
3.9.1 Gromacs, the MD Package 
The following is designed to acquaint you with the general features of the molecular dynamics 
software package Gromacs. Gromacs is a widely used molecular dynamics simulation package 
developed at the University of Groningen. Information on Gromacs can be found at 
http://www.gromacs.org/.  
To run a simulation several things are needed:  
o a file containing the coordinates for all atoms  
o information on the interactions (bond angles, charges, Van der Waals)  
o Parameters to control the simulation.  
The .pdb or .gro file contains the coordinates for all atoms and is the input structure file for MD 
simulation. The interactions are listed in the topology (.top) file and the input parameters are put 
into a .mdp file..  
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The actual steps in an MD simulation. 
o Conversion of the pdb structure file to a Gromacs structure file, with the simultaneous 
generation of a descriptive topology file.  
o Energy minimization of the structure to release strain.  
o Running full simulations.  
o Analyzing results.  
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CHAPTER 4 
 
 
 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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4. Materials and Methods: 
 
  
             Scheme 1: flowchart for designing the dual acting hybrid molecule.   
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4.1 Sequence alignment and Homology Modeling:  
The transmembrane portion of the H3 receptor was build by homology modeling techniques 
based on the 2.8 angstrom resolution crystal structure of Bovine Rhodopsin (pdb 1F88) 
which is the most accurate rhodopsin structure available. The primary sequence of the H3 
receptor was aligned with bovine rhodopsin, the CLUSTALW program was used from its 
web site at http://www2.ebi.ac.uk/CLUSTALW based upon highly conserved amino acid 
residues in the seven helices. A model of the human histamine H3 receptor was generated 
based on the crystal structure 1HZX of bovine rhodopsin.The initial sequence-structure 
alignment was based on multiple sequence alignments, the prediction of secondary structure, 
transmembrane helices and highly conserved residues identified. 
All homology models were constructed with the SWISS-MODEL server 
(http://expasy.org/swissmod/SWISSMODEL.HTML). And amino acid side chain 
conformations were added using program SCWRL3.0. . The model was validated for the 
stereochemical qualities were checked with  (http://nihserver.mbi.ucla.edu/SAVS/).  Finally, 
the structural properties of the target protein were validated by using the Ramachandran plot 
score.  
Molecular Redocking studies H3 and AchE receptors with   known active molecules: 
Docking study on H3 receptor 
Preparation of Ligands and Protein: 
Since ligands are not peptides, Gasteiger charge was assigned and then non-polar hydrogen‘s 
were merged. The rigid roots were defined automatically rather manually for each compound 
considered. The amide bonds were made non-rotatable. The homology model structure of was 
used for docking study The Kollman charges were added to each atoms of the modeled protein.  
Grid Generation: 
The Grid box was centered on the Asp 114 of the human histamine-3 receptor. The binding site 
includes the catalytic center (Asp 114  and  Glu 206) and several subsites as (Ser-79,Lec-82,Val-
83,Gly-84,Phe-86,Cys-87,Ile-88,Pro-89,Leu-90,Tyr-91,Trp-100,Leu-106,Cys-107,Lys-108,Leu-
109,Val-112,Val-113,Asp-114,Tyr-115,Leu-116,Leu-117,Cys-118,Thr-119,Ser-120,Trp-
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160,Tyr-167,Gly-168,Ile-171,Glu-175,Phe-192,Phe-198,Glu-206,Trp-371,Tyr-374,Met-378,Tyr-
394,Phe-398,Leu-401,Ser-405).The spacing between the Grid points was 0.375 angstroms. 
 
 
Docking: 
4.1.2 With autodock4 
Algorithm- Lamarckian genetic algorithm,Population size-150,Number of operations-
250000,Rate of Gene mutation -0.02,Rate of Crossover 0.8 
The parameters were set using the software Autodock Tools available at 
(http://mgltools.scripps.edu/downloads ) which is made to associate with Autodock 4.0 Binaries 
downloaded from (http://autodock.scripps.edu/downloads/autodock-registration). The 
Calculations of Autogrid and Autodock were performed on Linux operating system having 
system Properties (Intel(R) Pentium(R) D CPU 2.80GHz, 2.0 GB of RAM). 
4.1.3 With GOLD 
Algorithm- Lamarckian genetic algorithm, Population size-100, Selection pressure-1.1, Number 
of operations-100000, Number of islands-5, Niche size-2, Crossover frequency-95, Mutation 
frequency-95, Migration frequency-10. 
The Calculation was performed on windows operating system having system Properties (Intel(R) 
Pentium(R) D CPU 2.80GHz, 2.0 GB of RAM). 
4.2 QSAR study of Histamine-3 receptor  
4.2.1 Dataset: 
Dataset of 28 non-peptide Inhibitor molecules collected from the literature [30] , was considered 
in this study (figure 5). All the molecules studied had the same parent skeleton.). IC50 is the 
concentration of the compound leading to 50% inhibitory effect. The logarithm transformation of 
this parameter has been used as biological end points (log IC50) in the QSAR studies so as to 
move the data to a nearly normal distribution. 
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Fig 6:  The chemical structures of 28 Inhibitors(data taken from Gfesser et al[49]) 
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4.2.3  QSAR studies: 
2d QSAR STUDY 
Generation of molecular descriptors: 
 The selected 28 molecules were built and energy minimized using PRODRG software [25] and 
saved as the mol2 (output) files. The output files were loaded into Vlife MDS QSAR module for 
evaluation of several molecular descriptors along with the facility to build the QSAR equation 
and use it for predicting the activity of test/new molecules. These features are managed through 
an MS-Excel type worksheet. It can calculate all physiochemical descriptors such as Individual, 
Chi, Chiv, Path count, Chi Chain, Chiv chain, chain path count, Cluster, Path cluster, Kappa, 
Element count, Estate numbers, Estate contributions, Information theory index. Deselect Dipole 
Moment, Electro Static, Distance Based Topological Indices, Semi Empirical and 
Hydrophobicity base logP descriptors (as these are 3D descriptors) by the pointer 
Set Data to complete the selection of training and test set 
The worksheet shows the divisions of training data set (23molecules) and test data set (5 
molecules). 
Selection of data based on  
1. The max of the test should be less than max of train set 
2. The min of the test should be greater than min of train set 
 
Regression methods used: 
Multiple regressions 
Multiple regressions are the standard method for multivariate data analysis it is also called as 
ordinary least squares regression (OLS). This method of regression estimates the values of the 
regression coefficients by applying least squares curve fitting method 
Regression method- Multiple 
Selected variable selection method- Forward-backward, parameter setting- Cross correlation 
limits-1, Number variable in final equation-4, Term selection criteria-r
2
, Ftest-in-4.0. 
Regression method- Multiple 
Selected variable selection method- Genetic algorithm, Cross correlation limit-1.0, Population-10 
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Convergence criteria-0.01, Crossover probability-0.9, Number of generations-1000, 
Convergence length-3, Term selection criteria-r
2
, Seed-0 
Regression method- Multiple 
Selected variable selection method- Simulated annealing, Maximum temperature-100, Minimum 
temperature-0.01, Decrease tempratureby-10.0, Iteration at given temperature-5, Terms in 
model-4, Perturbation limits-1.0, Seed-0, Term selection criteria-r
2
 
 
Partial least squares regression method 
Partial least squares regression is an extension of the multiple linear regression model. In its 
simplest form, a linear model specifies the relationship between a dependent variable Y,and a set 
of predictor variable, the X‘s, so that 
Y=b0 + b1X1 +b2X2 +…+bpXp 
In this equation b0 is the regression coefficient for the intercept and the bi values are the 
regression coefficients (for variables 1 through p) computed from the data.\ 
Regression method- PLS 
Selected variable selection method- Forward-backward, parameter setting- Cross correlation 
limits-1, Number variable in final equation-4, Term selection criteria-r
2
, Ftest-in-4.0. 
Regression method- PLS 
Selected variable selection method- Genetic algorithm, Cross correlation limit-1.0, Population-10 
Convergence criteria-0.01, Crossover probability-0.9, Number of generations-1000, 
Convergence length-3, Term selection criteria-r
2
, Seed-0. 
Regression method- PLS 
Selected variable selection method- Simulated annealing, Maximum temperature-100, Minimum 
temperature-0.01, Decrease tempratureby-10.0, Iteration at given temperature-5, Terms in 
model-4, Perturbation limits-1.0, Seed-0, Term selection criteria-r
2 
 
Principle component regression (PCR) method 
Principle components analysis provides a method for finding structure in such data sets .put 
simply, rotates the data into a new set of axes, such that the first few axes reflect most of the 
variations within the data. By plotting the data on these axes, we can spot major underlying 
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structures automatically. The value of each point, when rotated to a given axis, is called the 
principle component values. 
Regression method- PCR 
Selected variable selection method- Forward-backward, parameter setting- Cross correlation 
limits-1, Number variable in final equation-4, Term selection criteria-r
2
, Ftest-in-4.0. 
Regression method- PCR 
Selected variable selection method- Genetic algorithm, Cross correlation limit-1.0, Population-10 
Convergence criteria-0.01, Crossover probability-0.9,Number of generations-1000, Convergence 
length-3, Term selection criteria-r
2
, Seed-0. 
Regression method- PCR 
Selected variable selection method- Simulated annealing, Maximum temperature-100, Minimum 
temperature-0.01, Decrease tempratureby-10.0, Iteration at given temperature-5, Terms in 
model-4, Perturbation limits-1.0, Seed-0, Term selection criteria-r
2
 
 
4.3.3 3D QSAR study 
 
k- nearest neighbor QSAR 
In k-nearest neighbor algorithm, for classifying a new pattern (molecule), 
The system finds the k nearest neighbors among the training set, and used the categories of the k-
nearest neighbors to weight the category candidates. The nearness is measured by an appropriate 
distance metric (e.g. a molecular similarity measure, calculated using descriptors of molecular 
structures). 
Method selected- k-nearest neighbor. 
Selected variable selection method- Forward-backward 
Parameter setting- Cross correlation limits-1, Number variable in final equation-4, Term 
selection criteria-q
2
, Ftest-in-4.0 
Method selected- k-nearest neighbor. 
Selected variable selection method- Simulated annealing. 
Parameter setting- Maximum temperature-100, Minimum temperature-0.01, Decrease 
tempratureby-10.0, Iteration at given temperature-5, Terms in model-4, Perturbation limits-1.0 
Seed-0, Term selection criteria-r
2
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  4.3.4 Docking study on AchE receptor 
Preparation of Ligands and Protein: 
Since ligand (tacrin, rivastigmine) are not peptides, Gasteiger charge was assigned and then non-
polar hydrogen‘s were merged. The rigid roots were defined automatically rather manually for 
each compound considered. The amide bonds were made non-rotatable. The PDB structure-
1EVE of was used for docking study The Kollman charges were added to each atoms of the 
given protein.  
Grid Generation: 
The Grid box was centered on the Ser 199, His 439 and Glu 326 of the AchE. The binding site 
includes several subsites as (TYR70, TRP84, GLY118, TYR 121, TYR130, GLU199, SER200, 
TRP279, LEU282, ILE287, PHE288, PHE290, GLU327, PHE331, TYR334, HIS440). The 
spacing between the Grid points was 0.375 angstroms. 
4.4 Molecular Dynamics Simulation Studies (best hybrid molecule) 
Gromacs is a very powerful molecular simulation package. The best hybrid molecule (results 
obtained from both GOLD and Autodock 4.0) was further analyzed for the stability of its 
interaction with the protein (histamine -3 receptor) using molecular dynamics simulation studies 
in Gromacs. The ligand-receptor complexes resulting from the docking calculation were placed 
in the box of water. 
Preparation of Ligand and Protein:   
A GMX topology file was prepared for the best docked molecule in Dundee PRODRG server 
(http://davapc1.bioch.dundee.ac.uk/programs/prodrg/). After putting drg.pdb coordinates into the 
empty text box on the webpage, Check the following options:(1).Chirality-Yes (2).Full charges- 
Yes (3).Energy Minimization- No Click "Run PRODRG". 
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DRGGMX.ITP file is used for building the topology for the drug. In addition, DRGFIN.GRO 
file is needed for building the coordinate file (*.GRO), or DRGPOH.PDB file can be used. The 
DRGGMX.ITP file was renamed to drg.itp. Our protein PDB file was too crude to use with 
pdb2gmx. So it was minimized in Chimera for 100 steps.  
Simulation: 
The topology file for the protein molecule was generated. The dodecahedron water box was set 
having diameter 0.65.The dodecahedron water box saves around 30% of computational time in 
comparison to cubic box. The system was found to have a non-zero total charge. So it was 
neutralized by adding Na+ ions in the water box. Na+ ions were added by simply replacing the 
water molecules in the water box.  
The energy minimization of protein molecule was done. "Steep" algorithm was used for energy 
minimization and no constraints were set during the process. The other parameters set for 
minimization as: emtol 2000, emstep 0.01, nstcomm 1, ns_type grid, rlist 1, coulomb type PME, 
rcoulomb 1.0, rvdw 1.4. No temperature coupling, pressure coupling was set and no velocity was 
generated during the process. The system was minimized to Fmax = 2000 in 1500 steps and the 
converged result came as:  
Steepest Descents converged to Fmax < 2000 in 832 steps 
Potential Energy = -1.5722345e+06 
Maximum force     = 1.6236754e+03 on atom 6800 
Norm of force     = 1.3176494e+04 
A position restrained dynamics simulation was run to "soak" the water and the drug into the 
drug-enzyme complex. In this run, the atom positions of the protein are restrained to restrict their 
movement in the simulation (i.e. the atom positions are restrained not fixed!). The water and the 
drug are permitted to relax about the protein. The relaxation time of water is 10 ps. Therefore, a 
total of 30 ps dynamics run was used to perform the soak under coulomb type, PME which 
stands for "Particle Mesh Ewald" electrostatics. PME is the best method for computing long 
range electrostatics (gives more reliable energy estimates). [6, 7] The all bonds option under 
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constraints applies the Linear Constraint algorithm [8] for fixing all bond lengths (important to 
use this option when dt > 0.001 ps). Berenson‘s temperature and pressure coupling methods were 
used [9]. The reference temperature was set at 300 K and the velocity was also generated. 
The molecular dynamics simulation parameters were set for the Gromacs 87 force field, which 
we are using. For this run, we use the energygrps parameter to establish the groups for the energy 
output (the md.edr file). This will be important for use in for example linear interaction energy 
computations later on. 
The parameters which were set for the final md simulation are as: 
Nsteps-= 5000000(number of steps (1ns), Coulomb type-= PME,   Vdwtype= Cut-off, Tcoupl= 
berendsen, Pcoupl = berendsen, pcoupltype = isotropic, constraints= all-bonds, constraint-
algorithm = shake  
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CHAPTER 5 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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5. RESULTS  
5.1 Sequence alignments and modeling H3 receptor 
Sequence alignment was done with the help of CLUSTALW software using default parameters. 
Because of an overall 60% sequence identity between the template and the target, as illustrated in 
Fig. 1, the generation of homology model of the human histamine h3 receptor was done using 
online Swiss model server (www.expasy.ch/swissmod/ SWISS-MODEL.html) based on the 
backbone coordinates of the crystal structure 1HZX of bovine rhodopsin. The missing side chain 
was added using the program SCWRL3.0. 
 
5.2 Structure Analysis and Verification  
PROCHEK was used to check the stereochemical quality of the protein structure generated, by 
analyzing residue-by-residue geometry and overall structural geometry. It tells about: Covalent 
geometry, Planarity, Dihedral angles, Chirality, Non-bonded interactions. The Ramchandran plot 
(Fig.7) was generated by PROCHEK of the protein model.  
Fig 7 Ramchandran plot of human histamine-3 receptor protein from PROCHECK.                  
 
 
Plot statistics 
 
Residues in most favored regions     [A,B,L]          306       
90.3% 
Residues in additional allowed regions [a,b,l,p]     24        
7.1% 
Residues in generously allowed regions [~a,~b,~l,~p] 6    1.8% 
Residues in disallowed regions                                  3        
0.9% 
---- -----------------------------------------------------------------------
- 
Number of non-glycine and non-proline residues  339     
100.0% 
Number of end-residues (excl. Gly and Pro)            2 
Number of glycine residues (shown as triangles)    32 
Number of proline residues                                   23 
---------------------------------------------------------------------------
-- 
Total number of residues                                      396 
---------------------------------------------------------------------------
-- 
Residue in disallow region are HIS417, THR-149, SER-330 
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.              
Fig 8: Homology model structure of histamine-3 receptor protein (cartoon view) 
5.3 Redocking study 
All 28 molecules were docked into the homology modeled protein of histamine receptor. The 
docking results were ranked according to the decreasing docking energies of the 100 conformers 
for each of the Ligands. It was found that most of the ligands with lowest docking energies 
interacted quite well with the receptor in the pocket. The molecules 11, 18, 23, 25 and 26 had the 
dock score of less than -8.00 kcal/mol. The docking study was done using Autodock4 software. 
The AchE receptor‘s pdb structure 1EVE and 1GQR were considered for docking along with the  
ligand molecules Rivastigmine and Tacrine  for docking studies. Out of the two PDB structures, 
1EVE showed good docking score that was less than -11.30 kcal/mol. The ligand Rivastigmine 
interacted well with the receptor binding pocket. Therefore, for our further studies we considered 
the PDB structure 1EVE for further investigations.  
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Figure1.(a) 
 
Figure1.(b) 
 Fig 9(a) Rivastigmine within the binding pocket.figure.1 (b) Residue interacting with the AchE 
receptor 
Table: (1): Binding free energies for the 28 molecules (Unmodified compounds) of both H3  
S.No Compounds Estimated 
Free Energy 
of Binding 
(kcal/mole) 
Estimated 
inhibition 
(µm) 
Final 
intermolecular 
energy(Vdr 
+H-bond 
+Dissolved 
energy) in 
kcal/mole  
Final total 
internal 
energy 
(kcal/mole) 
Torsional 
free energy 
(kcal/mole)  
Unbound 
system 
energy 
(kcal/mole) 
1 Compound1 -7.84 1.75 -8.45 +0.12 +1.10 -0.62 
2 Compound2 -7.71 2.23 -8.62 -0.61 +1.10 -0.42 
3 Compound3 -7.31 4.41 -8.16 -0.65 +1.10 -0.41 
4 Compound4 -6.37 3.83 -8.22 -0.67 +1.10 -0.41 
5 Compound5 -7.85 1.75 -8.68 -0.69 +1.10 -0.42 
6 Compound6 -7.08 6.48 -7.96 -0.68 +1.10 -0.44 
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7 Compound7 -6.20 28.59 -6.91 0.73 +1.10 -0.35 
8 Compound8 -7.18 5.41 -8.94 -0.59 +1.92 -0.43 
9 Compound9 -5.64 72.90 -7.10 -0.89 +1.92 -0.43 
10 Compound10 -6.88 9.03 -8.09 -0.80 +1.37 -0.64 
11 Compound11 -8.15 1.07 -9.04 -0.64 +1.10 -0.44 
12 Compound12 -6.17 30.26 -7.15 -0.50 +1.10 -0.38 
13 Compound13 -6.14 31.36 -7.95 -0.85 +2.20 -0.46 
14 Compound14 -7.14 5.86 -9.17 0.64 +2.20 -047 
15 Compound15 -7.57 2.81 -8.68 -0.72 +1.37 -0.46 
16 Compound16 -7.14 3.71 -8.82 -0.43 +1.37 -0.47 
17 Compound17 -7.57 2.84 -8.85 -0.63 +1.37 -0.54 
18 Compound18 -8.54 0.547 -9.45 -0.61 +1.65 -0.43 
19 Compound19 -7.85 1.70 -8.48 -0.12 +165 -0.43 
20 Compound20 -6.88 8.99 -7.91 -0.53 +1.10 -0.45 
21 Compound21 -7.06 6.68 -7.87 -0.74 +1.10 -0.45 
22 Compound22 -7.60 2.07 -8.97 -0.80 +1.65 -0.53 
23 Compound23 -8.43 0.66 -9.60 -0.72 +1.37 -0.52 
24 Compound24 -7.45 3.46 -8.96 -0.57 +1.65 -0.43 
25 Compound25 -8.01 1.34 -9.48 --0.61 +1.65 -0.43 
26 Compound26 -8.00 1.37 -8.88 -0.65 +1.10 -0.43 
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Table: (2): Binding free energies for the pharmaceutical compound Rivastigmine with PDB 
structures (1EVE, 1GQR) 
 
 
 
 
 
 
 
 
 
27 Compound27 -7.27 4.71 -8.28 -0.44 +1.10 -0.36 
28 Compound28 -6.44 19.01 -7.08 -0.84 +1.10 -0.38 
S.No Compound    
Name 
Estimated 
Free 
Energy of 
Binding 
(kcal/mole) 
Estimated 
inhibition  
Final 
intermolecular 
energy(Vdr 
+H-bond 
+Dissolved 
energy) in 
kcal/mole 
Final total 
internal 
energy 
(kcal/mole) 
Torsional 
free energy 
(kcal/mole) 
Unbound 
system 
energy 
(kcal/mole) 
1 1EVE-
RIVASTGMINE 
-11.35 4.75nm -12.98 -0.70 +1.65 -0.68 
2 1GQR-
RIVASTGMINE 
-9.63 86.82nm -10.18 -0.20 -1.37 -0.01 
74 
 
Table: (3) Comparison of the MR,SA-MR,GA-MR,PLS,SA-PLS,GA-PLS,PCR,SA-PCR,GA-
PCR models for the aryl benzo data set using the selected data set. 
Two-dimensional QSAR 
parameter/molecule actual MR SA-MR GA-MR PLS SA-PLS GA-PLS 
r2  0.7602 0.7637 0.5977 0.8222 0.4986 0.7148 
q2  0.4869 0.4224 0.2859 -0.2345 -0.2630 0.2570 
F-Test  20.0721 10.9900 9.4098 29.2872 9.9458 25.0679 
r2 se  0.2933 0.2850 0.3517 0.2338 0.3827 0.2886 
q2 se  0.4290 0.4455 0.4686 0.6161 0.6074 0.4659 
pred_r2  0.3206 0.6649 0.7019 0.8041 0.4175 0.7465 
pred_r2 se  0.5046 0.4602 0.4340 0.3519 0.6067 0.4002 
 
 
 
SELECTED 
DESCRIPTORS 
 Polar surface 
area 
excluding 
PandS, 
SssOE-index, 
T_2_C_4.  
 
T_2_2_5, 
T_C_N_7, 
SssOHcount
, 
T_C_F_3, 
SsCH3E-
index 
Polar 
surface 
area 
excluding 
PandS, 
T_C_N_6, 
T_O_O_0. 
Polar 
surface 
area 
excluding 
PandS, 
T_2_2_5, 
SssOE-
index, 
T_O_O_7, 
T_O_O_2. 
ChiV5, 
Polar 
surface 
area 
excluding 
PandS, 
T_2_2_0. 
T_T_N_3, 
CHIv0, 
T_2_2_4, 
SsOHE-
index, 
SsCH3E-
index. 
Test data        
Molecule-2 9.569 9.3298 9.0263 9.0230 9.1737 8.8160 9.1278 
Molecule-4 8.658 8.2758 8.3146 8.3474 8.3263 8.1845 8.4352 
Molecule-8 8.244 8.3478 8.3650 8.3474 8.3263 8.1427 8.2833 
Molecule-14 7.959 8.2537 8.3273 8.2184 8.2390 8.5731 8.2339 
Molecule-27 8.699 9.5460 9.0197 9.0230 9.1737 9.0109 8.9878 
parameter/molecule actual PCR(Forward
) 
SA-PCR GA-PCR 
r2  0.7646 0.7017 0.3254 
q2  0.3449 0.2556 -0.0750 
F-Test  20.5721 10.5836 10.1298 
r2 se  0.2690 0.3112 0.4332 
q2 se  0.4488 0.4916 0.5469 
pred_r2  0.8450 0.6729 0.0858 
pred_r2 se  0.3130 0.4546 0.7601 
 
SELECTED 
DESCRIPTORS 
 Polar surface 
area 
excluding 
PandS, 
T_2_2_5, 
T_O_O_2, 
SssOcount. 
 
SaaCHcount 
SsOHcount, 
T_T_N_4, 
T_2_2_6, 
SsCH3E-
index, 
ChiV1, 
Polar 
surface 
area 
excluding 
PandS, 
T_2_2_0. 
 
Test data     
Molecule-2 9.569 9.2038 9.0370 8.5937 
Molecule-4 8.658 8.3500 8.3048 8.1442 
Molecule-8 8.244 8.3500 8.3049 8.4579 
Molecule-14 7.959 8.1336 8.3049 8.6562 
Molecule-27 8.699 9.2038 9.0093 8.8020 
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28 molecules which were taken from the literature were divided into two parts, one is test set and 
others into training set in 1:4 ratio and the test set had maximum and minimum IC50 value less 
than the respective IC50 values of training set. Different 2D QSAR methods are used such as SW, 
GA, MR using some sets of training and test set. This QSAR showed different q
2
 values which 
ranged from 0.4986 and 0.8222. Different descriptors having different q
2 
were obtained. To make 
a common set out of these different descriptors with different q
2
 values all the 20 different 
descriptors were put into the neural network. The q
2
 value thus generated which is more then 
0.89(i.e. around 90%   in prediction of IC50 value). 
QSAR MODEL USING NEURAL NETWORK 
Method -Back propagation 
Training set size=23, Test set size=5 
selected descriptors- ChiV1, Polar surface area excluding PandS, SaaCHcount, 
T_T_N_4,T_2_2_6, T_2_2_5, T_O_O_2,SssOcount, T_2_C_4, 
T_2_2_5,T_C_N_7,SssOHcount,T_C_F_3,SsCH3E-index, T_C_N_6, T_2_2_5, SssOE-
index,T_O_O_7,T_O_O_2,T_O_O_0, , T_2_2_0, T_T_N_3,CHIv0,T_2_2_4,SsOHE-index. 
Statics-   N=23, degree of freedom=1, r
2
 =0.9595, F Test =1.1278, pred_r
2
 =0.7382, pred_r
2
se 
=0.3132 
 
 
Fig 10 Plot of the observed vs. calculated pki values the binding affinities to the H3 receptors 
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The relationship between different types of descriptors with activity is shown in graph. 
Table: (4) selected descriptors with their function    
 
ChiV0 atomic valence connectivity index (order 0)  
ChiV1  atomic valence connectivity index (order 1) 
SaaCHcount  the total number of carbon atoms connected with a hydrogen along with two 
aromatic bonds 
SsOHcount the total number of –OH group connected with one single bond. 
 
SssOcount total number of oxygen connected with two single bonds. 
 
SsCH3E-index Electro topological state indices for number of -CH3 group connected with one 
single bond. 
SsOHE-index Electro topological state indices for number of –OH group connected with one 
single bond. 
SssOE-index Electro topological state indices for number of oxygen atom connected with 
two single bonds 
Polar Surface 
Area 
Excluding 
PandS 
total polar surface area excluding phosphorous and sulphur. 
 
T_2_2_0 the count of number of double bounded atoms (i.e. any double 
bonded atom, T_2) separated from any other double bonded atom by 0 bonds in 
a 
molecule. 
 
T_2_2_4 number of double bounded atoms (i.e. any double 
bonded atom, T_2) separated from any other double bonded atom by 4 bonds in 
a 
molecule. 
 
T_2_2_5 number of double bounded atoms (i.e. any double 
bonded atom, T_2) separated from any other double bonded atom by 5 bonds in 
a 
molecule. 
 
T_2_2_6 This is the count of number of double bounded atoms (i.e. any double 
bonded atom, T_2) separated from any other double bonded atom by 6 bonds in 
a 
molecule. 
 
T_2_C_4 number of double bounded atoms (i.e. any double 
bonded atom, T_2) separated from carbon atom by 4 bonds in a molecule 
T_C_N_7 of number of Carbon atoms (single double or triple 
bonded) separated from any nitrogen atom (single or double bonded) by 7 bond 
77 
 
 
 
 
 
 
 
 
 
 
 
distance in a molecule. 
 
T_C_N_6 
 
number of Carbon atoms (single double or triple 
bonded) separated from any nitrogen atom (single or double bonded) by 6 bond 
distance in a molecule. 
 
T_C_F_3  number of Carbon atoms (single double or triple 
bonded) separated from any nitrogen atom (single or double bonded) by 3 bond 
distance in a molecule. 
 
T_C_N_6  number of Carbon atoms (single double or triple 
bonded) separated from any nitrogen atom (single or double bonded) by 6 bond 
distance in a molecule. 
 
T_O_O_2  the count of number of oxygen atoms (single double or triple 
bonded) separated from any oxygen atom (single or double bonded) by 2 bond 
distance in a molecule. 
 
T_O_O_0 number of oxygen atoms (single double or triple 
bonded) separated from any oxygen atom (single or double bonded) by 0 bond 
distance in a molecule 
T_O_O_7 number of oxygen atoms (single double or triple 
bonded) separated from any oxygen atom (single or double bonded) by 7 bond 
distance in a molecule 
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Interpretation and comparison of SW-KNNMFA and SA-KNNMFA 3d 
QSAR model 
In our QSAR study it can be seen that the KNNMFA models obtained by using two  variable 
selection methods shows that steric potential(1 out 3 in SW and 3 out of three in SA) and the 
descriptors  S_275 common in both generated models. 
Descriptors range for SA-KNNMFA 
 Electrorostatic –E_ 655(30.0000, 30.0000), E_584 (10.0000, 10.00000) 
Steric potential -S_725 (7.7104, 30.0000) 
 Descriptors range for SW-KNNMFA 
 Steric potential -S_725 (7.7104, 30.0000), S_795 (-0.3099, 30.0000), S_675 (-0.0113, 30.0000) 
Positive range indicates that positive electrostatic potential is favorable for increase in the 
activity and hence a less electronegative substituent group is preferred in that region. Negative 
range indicates that negative steric potential is favorable for increase in the activity and hence 
less bulky substituent group is preferred in that region. Positive range indicates that positive 
steric potential is favorable for increase in the activity and hence more bulky substituent group is 
preferred in that region. 
  Table: (5) Comparison of k-Nearest Neighbor Method for the histamine-3 data set using the 
optimal test set of 5 molecules. 
parameter/molecule actual SW kNN-MFA SA kNN-MFA 
q
2
  0.6154 0.5223 
q
2 
_se  0.3364 0.3749 
pred_r
2
         0.6240 0.1125 
pred_r
2
 se          0.8810 0.6513 
descriptors 
 
 
 
 S_725,S_675, 
S_795.  
S_725,E_655, 
E_584 
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     Fig 13 .Distribution of chosen points in the SA kNN-MFA for the aryl benzo data set with the 
selected test set molecule  
    
      Fig 14 .Distribution of chosen points in the SA kNN-MFA for the aryl benzo data set with 
the selected test set molecule 
Table: (6) 3d-QSAR data  k-Nearest Neighbor Method. 
               SA kNN-MFA model  
 
                 SW kNN-MFA model 
 
                        Test 
data 
Actual  Predicted                          Test 
data 
Actual  Predicted  
Molecule-1 9.347 9.6590 Molecule-1 9.347 9.5690 
Molecule-4 8.658 7.9590 Molecule-4 8.658 8.3010 
Molecule-10 8.102 8.7210 Molecule-10 8.102 9.5690 
80 
 
Molecule-21 8.444 8.2290 Molecule-21 8.444 8.2290 
Molecule-28 9.553 8.6990 Molecule-28 9.553 8.6990 
                       Training data                         Training data 
Molecule-2 9.569 8.9210 Molecule-2 9.569 9.0560 
Molecule-3 8.495 8.2010 Molecule-3 8.495 8.2010 
Molecule-5 8.201 8.1190 Molecule-5 8.201 8.1140 
Molecule-6 8.301 8.2760 Molecule-6 8.301 8.3010 
Molecule-7 8.276 8.3870 Molecule-7 8.276 8.3010 
Molecule-8 8.244 8.4090 Molecule-8 8.244 8.4090 
Molecule-9 8.409 8.2440 Molecule-9 8.409 8.2440 
Molecule-11 8.569 8.2290 Molecule-11 8.569 8.2290 
Molecule-12 8.387 8.2760 Molecule-12 8.387 8.3010 
Molecule-13 8.119 8.2010 Molecule-13 8.119 8.1140 
Molecule-14 7.959 8.3010 Molecule-15 8.041 8.3010 
Molecule-15 8.041 8.4410 Molecule-16 8.921 8.4090 
Molecule-16 8.921 8.4090 Molecule-17 7.824 8.444 
Molecule-17 7.824 8.2760 Molecule-18 8.444 8.3010 
Molecule-18 8.444 8.4950 Molecule-19 8.301 8.1140 
Molecule-19 8.301 8.3870 Molecule-20 8.229 8.3010 
Molecule-20 8.229 8.5690 Molecule-22 8.721 8.9210 
Molecule-22 8.721 8.6990 Molecule-23 10.076 9.3100 
Molecule-23 10.076 9.3100 Molecule-24 9.056 9.5690 
Molecule-24 9.056 9.5690 Molecule-25 9.310 8.9210 
Molecule-25 9.310 8.4090 Molecule-26 8.114 8.2010 
Molecule-26 8.114 8.1190 Molecule-27 9.5530 8.4090 
Molecule-27 8.6990 8.7210 Molecule-2 9.569 9.0560 
 
Pharmacophore study of AchE  
Using crystal structure of rivastigmine in the active site of AchE. After redocking study revels 
two set of key interaction between the protein and the ligand. One set of interaction between the 
trp83 (located at the base of the active site) and quaternary amine of rivastigmine and second 
interaction of trp278 located at the opening of the cavity. 
 
 
 
 
 
 
 
81 
 
Pharmacophore study of histamine-3 antagonist   
.  
 
      Fig 15 .Distribution of chosen points in the SA kNN-MFA for the aryl benzo data set with 
the selected test set molecule 
 
5.5 Molecular hybrid 
 
One of the quaternary amine out of two quaternary amine well fits with it. Quaternary amine of 
AchE inhibitor and h3 antagonist are well fit.So combining two class of molecule at that 
quaternary amine portion without changing the pharmacophore of other five hybrid design. 
Molecular hybridization of histamine receptor antagonists and AchE inhibitors.5 proposals of 
molecular hybridization involving Tacrine and Rivastigmine for AchE inhibitor activity and H3 
antagonist with best IC50 value. The entire 5 hybrids molecule passed through Lipinski five rules 
and none of them violated this rule. Toxicity predictions are done through ADME/TOX filter. Our 
main goal was to design an H3 receptor antagonist capable of inhibiting AchE. Here we use the crystal 
structure data of AchE (1EVE). And use the knowledge of the 2d QSAR, 3D QSAR and 3d 
pharmacophore of H3 receptor 
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                                                                               (a) 
 
                                                                    (b) 
Scheme 2. (a) Derivatives 1, 2, 3 molecular hybridization of rivastigmine with arylbenzofuran ;( 
b) derivatives 4, 5 molecular hybridization of tacrine with arylbenzofuran 
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Validation of five hybrids  
Out of  all five hybrid the binding mode of hybrid-3,2,4 very much overlaid with the crystal 
structure binding mode of decamethonium 1eve.good superposition between the donepezil 
structure oriented with gold and the same molecule in the crystallographic orientation  suggest 
the method used appropriate. 
Table: (7) gold dock score of proposed compound with histamine-3  receptor. 
Molecule name Fitness S(hb_ext) S(vdw_ext)   S(hb_int) S(int) 
Arylbenzofuran 42.51 1.92 42.20 0.00 -17.44 
Proposal-1 
 
13.40 1.36 45.35 0.00 -50.32 
Proposal-2 
 
57.07 0.00 51.97 0.00 -14.39 
Proposal-3 
 
76.62 11.51 63.14 0.00 -23.89 
Proposal-4 
 
45.92 6.88 41.86 0.00 -18.52 
Proposal-5 57.35 0.35 55.41 0.00 -19.19 
 
                 Proposed compound-3                                   proposed compound-2 
 
84 
 
 
 
                  Proposed compound-4 
 
 
 
Fig 15. Details of the AchE active site in which the superposition of the crystallographic 
orientation of donepezil with the top 3 ranked solution suggested by GOLD is shown. 
 
 
 
 
    
 
Table: (8) Gold dock score of proposed compound with AchE receptor. 
 
Molecule name Fitness S(hb_ext) S(vdw_ext)   S(hb_int) S(int) 
Donepezil  56.95 0.30 49.79 0.00 -11.82 
Proposal-1 
 
59.14 2.19 61.93 0.00 -28.20 
Proposal-2 
 
61.14 1.25 51.45 0.00 -10.85 
Proposal-3 
 
81.75 11.51 65.42 0.00 -19.71 
Proposal-4 
 
68.71 10.15 53.67 0.00 -15.24 
Proposal-5 
 
69.24 6.01 59.58 0.00 -18.68 
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The conformation of highest score obtained with gold for this proposal-3(score=81) and it almost 
align with the rivastigmine Donepezil in pdb and for histamine-3 receptor proposed compound 
shows highest score. 
Molecular dynamic simulation MD simulation  
The ligand –receptor complex resulting from docking calculation were placed in a box of water 
using algorithms was carries out for 1ns after initially equilibrated water molecules for 50 ns. An 
average structure was energy minimized under conjugated gradient and periodic boundary 
condition. The dynamic behavior and structural change of the receptor was analyzed by 
calculating the RMSD value for structural movement and change in the elements of secondary 
structure of the receptor model during the MD simulation. 
The structure change of h3 receptor model was evaluated during 1ns MD simulation by use of 
GROMACS 3.3.1It can be seen from Fig 17 that the potential energy of the h3 receptor model 
Ligands reaches to the plateau (2.0 A
0
) with in first 200ps. 
 
a  b  
Fig 16 (a). Potential energy graph of protein –ligand complex during 1ns molecular simulation in 
the active site using GROMACS 3.3.1; (b) Avg structure during last 50 ps simulation in solvated 
condition. 
Potential energy of protein-ligand complex remain in range between -2.12e+06 to -
2.13e+06KJ/mol  and the histamine-3 receptor backbone reaches a constant level after  250 ps at 
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2.0 A
0
,but suddenly increases after 460 ps at 2.5 A
0 
 and  then remain same for 1ns simulation 
time period .  
The H-bond between drug molecule and enzyme were analyzed and after calculating the average 
of all H-bond candidates total 3 H-bonds were observed between ligand and receptor molecule. 
The RMSD plots of protein backbone and the drug were obtained separately (Fig18 & Fig17 
respectively). The backbone RMSD indicates that the rigid protein structure equilibrates rather 
quickly in this simulation (after 20 ps). The drug does not equilibrate until after 30 ps. The 
RMSD for the drug is more variable indicative of its mobility within the binding pocket. 
 
Fig 17. Plot showing the RMSD deviation of ligand in the solvated protein during 1ns molecular 
simulation in the active site using GROMACS 3.3.1 
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Fig 18. Plot showing the RMSD deviation of l in the solvated protein back bone during 1ns 
molecular simulation in the active site using GROMACS 3.3.1 
 
The RMSD close to 3.5A
0
  (for backbone) and 2.5 A
0
  (for drug molecule) and fairly low 
potential energy close to -2.12e+06 to -2.13e+06 KJ/mol shows high stability of protein-ligand 
complex shows the likeliness of ligand molecule to be drug like candidates 
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CHAPTER 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION  
                                        
In this work, combined 2D QSAR study was carried out using various statistical models. Using 
all the models, 20 best descriptors were selected. Further, these descriptors were used in neural 
network back propagation model as a training set to conclude to a given result(Table 3 ). The 
value of cross validated squared correlation coefficient ―q2‖ generated more than 0.89 (i.e. 
around 90% accurate in prediction of IC50 value) suggests a good internal productivity of the 
equation. The equation generated describes the positive contribution of Chiv 0, SssOE-index, 
SssCH3-index, Polar Surface Area excluding P and S whereas Chiv1, SssO count, SaaCHcount 
descriptors contributed negative to the inhibitory activity. From 3D QSAR study using SW kNN-
MFA and SA kNN-MFA shows that steric potential (1 out of 3 descriptors in SA, 3 out of 3 
descriptors in SW are steric potential descriptors) plays major role in determining biological 
activity. The descriptor S_725 (7.7104, 30.0000) was common in both generated model. 
Statistically, SW kNN-MFA model is comparatively better as compared to SA kNN-MFA with 
respect to q
2
=0.6154. In the second part of this work, five novel molecular hybrids of the 
pharmaceuticals Tacrine, rivastigmine and aryl benzofuran, used in the Alzheimer‘s disease 
(AD), was designed and evaluated for further investigation and experimental validation. Based 
on this work, the hybrids proposed have shown very close orientations to the original 
pharmaceuticals. Our results suggest that the proposal-3, with highest synthetic viability, has 
more interactions with the both AchE and histamine-3 receptor. During molecular dynamic 
studies done with Histamine-3 receptor using GROMACS identified the amino acid residues 
responsible for the formation of the hydrogen bonding with TYR-59 (tyrosine residue number 
59). We propose that this molecule is an interesting pharmaceutical candidate for preparation and 
further investigation of various wet lab studies. 
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